- Published on
Infectious Disease - Diphtheria
DIPHTHERIA
Basics: Obstructive laryngotracheitis, which can cause trouble breathing, or pseudomembrane formation on the tonsils, pharynx, larynx, and nasal cavity are signs of an acute upper respiratory tract infection caused by Corynebacterium diphtheriae. Acute tubular necrosis, peripheral neuropathies, and myocarditis are further possible outcomes of infection. C. diphtheriae can also produce lesser skin-only illnesses.
The study of epidemiology
Since 1980, the US has seen an incidence of about 0.001 instances per 100,000 people. Prior to vaccination, in the 1920s, there were between 100–200 cases per 100,000 people.
The frequency
Preschool-aged children have the highest attack rate; recent, infrequent outbreaks have mostly impacted adults; it is still endemic in portions of Africa, the Americas, the Middle East, Asia, the South Pacific, and Europe.
• It is more prevalent during the colder months in temperate zones; in the tropics, seasonal variations are less pronounced.
RISK ELEMENTS
Low socioeconomic position, lack of or insufficient immunization, crowded and filthy living conditions, immunocompromise, and travel to endemic or ongoing epidemic areas, particularly for those without a diphtheria toxoid booster
Genetics
No clear genetic connection to illness
GENERAL PREVENTION • Health education highlighting the risks of contracting diphtheria and the value of vaccination • Immunization with diphtheria toxoid
• Every ten years, diphtheria toxoid is promoted; the government is dedicated to immunization and other public health initiatives.
Tight disease control protocols during outbreaks: Notify the Department of Health of cases; isolate and treat patients
Clean all items that come into contact with the patient; isolate patient contacts who work with food, particularly milk, and those who come into contact with youngsters who are not inoculated; look into the cause of the infection; Preventive care for infection carriers
Pathophysiology
Exotoxin is released by C. diphtheria when it adheres to mucosal epithelial cells; it causes a local inflammatory response that is followed by tissue destruction and necrosis; it causes proteolytic cleavage of the cell membrane, which allows segment A to enter the cell; it inhibits host cell protein synthesis and results in cell death; and it spreads through the lymphatic and hematological systems, causing systemic disease.
Ethiology
• Caused by C. diphtheriae strains infected with a lysogenic bacteriophage virus that carries a gene that codes for a toxin.
• The incubation time is 2–5 days (with a range of 1–10).
C. diphtheriae are aerobic, pleomorphic, Gram-positive, nonmotile bacilli that mostly infect humans.
• The organism may colonize the respiratory tract without causing illness; it is spread via respiratory droplets, contact with nasopharyngeal secretions, exudates from cutaneous lesions, and fomites.
COMMON CONNECTED CIRCUMSTANCES
No conditions that are frequently linked
History of Diagnosis
• Signs, such as chills and fevers
Weakness and malaise; cough, hoarse voice, sore throat, and dysphagia Cervical lymphedema
- Headache - Serosanguineous or purulent nasal discharge - Neck edema - Nasopharyngeal membrane formation - Dyspnea, wheezing
Lesions on the skin
• Travel history; • Immunocompromising conditions; • History of vaccinations, including booster shots;
• Drinking unpasteurized dairy products
Physical examination • Fever of low severity
Swelling of the neck or "bull's neck"; tachycardia; pseudomembrane (grey and adherent) on the tonsils, pharynx, or nasal membranes; bleeding in the underlying mucosa when the pseudomembrane is scraped off; halitosis; cervical lymphadenopathy; respiratory distress symptoms such as stridor, wheeze, cyanosis, and use of accessory muscles; dysrhythmias; indications of infective endocarditis; and deficits in the cranium or peripheral nerves
Initial diagnostic and interpretation lab tests
Moderate leukocytosis is seen in the complete blood count (CBC); temporary proteinuria is seen in the urine analysis.
• Levels of serum troponin-I
• The isolation of C. diphtheriae in culture and the detection of toxin presence serve as the foundation for a conclusive diagnosis.
• C. diphtheriae was isolated using Gram stain, which revealed clusters of club-shaped, nonencapsulated, nonmotile bacilli with a distinctive Chinese character configuration.
Cultures: Use nasal or throat swabs to inoculate tellurite or Loeffler media, then identify the colonies based on their morphology, microscopic appearance, and fermentation reactions.
• Polymerase chain reaction (PCR) for tox genes; Elek test; Toxin detection
Follow-up and Particular Points to Remember
Keep an eye on your CBC and 12-lead ECG.
Imaging first approach: computed topography, ultrasound scan, or chest radiograph; soft tissue radiography of the neck
Follow-up and Particular Points to Remember
Nothing
Diagnostic Tests and Other Services: Patients may need:
Surgical airway procedures such as cricothyroidotomy or tracheostomy; laryngoscopy or bronchoscopy; endotracheal intubation; and electrical pacing for conduction problems
Pathological Results
The tonsils, pharynx, larynx, and nasal mucosa all have pseudomembranes, which can be aspirated into the lungs.
DISTINCTIVE DIAGNOSIS
Vincent's angina, viral pharyngitis, streptococcal pharyngitis, infectious mononucleosis, epiglottitis, infectious endocarditis, and herpes simplex virus
MEDICATION FOR TREATMENT
First Phrase
• Since horses produce diphtheria antitoxin (DAT) and patients may experience a hypersensitive reaction to horse antiserum, DAT should be given as soon as possible. With epinephrine and cardiac resuscitation resources nearby, a test dose is necessary.
• Antibiotics: Penicillin G 300,000 U/d for 14 days in patients under 10 kg i.m.
600,000 U/d for 14 days for patients weighing more than 10 kg i.m.
Erythromycin (for people who are allergic to penicillins) Adult: 500 mg intravenously every six hours for 14 days
Vancomycin for children: 40–50 mg/kg/day p.o./i.v., divided into 6 hourly doses for 14 days
Adult: given intravenously (1 g every 12 hours)
Children: intravenous infusion of 40 mg/kg/d over 1 hour, divided into 6 hourly doses; bronchodilators; antipyrexials; second-line pharmaceutical therapy as described above
ADDITIONAL MEDICATION
Overall Actions
Patients should be isolated as soon as possible. Two large-bore intravenous cannulae should be inserted. Cardiac monitoring should be done.
Referral issues include the following: anesthetist for airway management; surgery for surgical airway; cardiology for myocarditis; respiratory medication for bronchoscopy for pseudomembrane removal or obstruction; renal medication for acute tubular necrosis; and neurology for peripheral nerve damage.
ALTERNATIVE AND COMPLIMENTARY THERAPIES
Physiotherapy for neurological conditions
OTHER PROCEDURES AND SURGERY
Surgical airway may be necessary.
Considering the patient
First Stabilization
Provide patients with adequate resuscitation in accordance with pediatric basic life-support or advanced life support (ALS) procedures.
Requirements for Admission
Individuals with heart failure, septicemia, pulmonary compromise, or symptoms of infective endocarditis
IV fluids; aggressive fluid resuscitation in septic shock patients using colloids, such as Gelofusin
• When necessary, maintenance fluids containing Ringer's lactate
Until two nasopharyngeal swab cultures, obtained 24 and 48 hours after stopping antibiotics, are negative, nurses should isolate patients using universal and droplet precautions.
Criteria for Discharge
• Individuals with the two negative swabs mentioned above; • No indications of respiratory distress; • Stability of hemodynamics
Continuing Care Follow-Up Suggestions
Complete the age-appropriate immunization schedule; administer erythromycin or penicillin for 14 days to household members and close contacts; and get follow-up nasopharyngeal cultures to verify the eradication of bacteria.
DIET: Pasteurization is recommended for all dairy products.
PATIENT EDUCATION • Completing the age-appropriate immunization schedule is crucial • Seeking treatment as soon as an infection is suspected
Cardiac involvement is linked to a very poor prognosis.
prognosis; bacteremia mortality rates of 30–40%; high mortality rates in individuals under age 5 and those over age 40
Problems include: septicemia or septic shock; septic arthritis, osteomyelitis; myocarditis, cardiac dilatation and failure, mycotic aneurysm, endocarditis; cardiac rhythm abnormalities; secondary bacterial pneumonia; cranial nerve dysfunction, peripheral neuropathies, and complete paralysis; optic neuritis; acute tubular necrosis; and septicemia or septic shock. Five to ten percent of respiratory cases result in death.
DIPHTHERIA
Basics: Obstructive laryngotracheitis, which can cause trouble breathing, or pseudomembrane formation on the tonsils, pharynx, larynx, and nasal cavity are signs of an acute upper respiratory tract infection caused by Corynebacterium diphtheriae. Acute tubular necrosis, peripheral neuropathies, and myocarditis are further possible outcomes of infection. C. diphtheriae can also produce lesser skin-only illnesses.
The study of epidemiology
Since 1980, the US has seen an incidence of about 0.001 instances per 100,000 people. Prior to vaccination, in the 1920s, there were between 100–200 cases per 100,000 people.
The frequency
Preschool-aged children have the highest attack rate; recent, infrequent outbreaks have mostly impacted adults; it is still endemic in portions of Africa, the Americas, the Middle East, Asia, the South Pacific, and Europe.
• It is more prevalent during the colder months in temperate zones; in the tropics, seasonal variations are less pronounced.
RISK ELEMENTS
Low socioeconomic position, lack of or insufficient immunization, crowded and filthy living conditions, immunocompromise, and travel to endemic or ongoing epidemic areas, particularly for those without a diphtheria toxoid booster
Genetics
No clear genetic connection to illness
GENERAL PREVENTION • Health education highlighting the risks of contracting diphtheria and the value of vaccination • Immunization with diphtheria toxoid
• Every ten years, diphtheria toxoid is promoted; the government is dedicated to immunization and other public health initiatives.
Tight disease control protocols during outbreaks: Notify the Department of Health of cases; isolate and treat patients
Clean all items that come into contact with the patient; isolate patient contacts who work with food, particularly milk, and those who come into contact with youngsters who are not inoculated; look into the cause of the infection; Preventive care for infection carriers
Pathophysiology
Exotoxin is released by C. diphtheria when it adheres to mucosal epithelial cells; it causes a local inflammatory response that is followed by tissue destruction and necrosis; it causes proteolytic cleavage of the cell membrane, which allows segment A to enter the cell; it inhibits host cell protein synthesis and results in cell death; and it spreads through the lymphatic and hematological systems, causing systemic disease.
Ethiology
• Caused by C. diphtheriae strains infected with a lysogenic bacteriophage virus that carries a gene that codes for a toxin.
• The incubation time is 2–5 days (with a range of 1–10).
C. diphtheriae are aerobic, pleomorphic, Gram-positive, nonmotile bacilli that mostly infect humans.
• The organism may colonize the respiratory tract without causing illness; it is spread via respiratory droplets, contact with nasopharyngeal secretions, exudates from cutaneous lesions, and fomites.
COMMON CONNECTED CIRCUMSTANCES
No conditions that are frequently linked
History of Diagnosis
• Signs, such as chills and fevers
Weakness and malaise; cough, hoarse voice, sore throat, and dysphagia Cervical lymphedema
- Headache - Serosanguineous or purulent nasal discharge - Neck edema - Nasopharyngeal membrane formation - Dyspnea, wheezing
Lesions on the skin
• Travel history; • Immunocompromising conditions; • History of vaccinations, including booster shots;
• Drinking unpasteurized dairy products
Physical examination • Fever of low severity
Swelling of the neck or "bull's neck"; tachycardia; pseudomembrane (grey and adherent) on the tonsils, pharynx, or nasal membranes; bleeding in the underlying mucosa when the pseudomembrane is scraped off; halitosis; cervical lymphadenopathy; respiratory distress symptoms such as stridor, wheeze, cyanosis, and use of accessory muscles; dysrhythmias; indications of infective endocarditis; and deficits in the cranium or peripheral nerves
Initial diagnostic and interpretation lab tests
Moderate leukocytosis is seen in the complete blood count (CBC); temporary proteinuria is seen in the urine analysis.
• Levels of serum troponin-I
• The isolation of C. diphtheriae in culture and the detection of toxin presence serve as the foundation for a conclusive diagnosis.
• C. diphtheriae was isolated using Gram stain, which revealed clusters of club-shaped, nonencapsulated, nonmotile bacilli with a distinctive Chinese character configuration.
Cultures: Use nasal or throat swabs to inoculate tellurite or Loeffler media, then identify the colonies based on their morphology, microscopic appearance, and fermentation reactions.
• Polymerase chain reaction (PCR) for tox genes; Elek test; Toxin detection
Follow-up and Particular Points to Remember
Keep an eye on your CBC and 12-lead ECG.
Imaging first approach: computed topography, ultrasound scan, or chest radiograph; soft tissue radiography of the neck
Follow-up and Particular Points to Remember
Nothing
Diagnostic Tests and Other Services: Patients may need:
Surgical airway procedures such as cricothyroidotomy or tracheostomy; laryngoscopy or bronchoscopy; endotracheal intubation; and electrical pacing for conduction problems
Pathological Results
The tonsils, pharynx, larynx, and nasal mucosa all have pseudomembranes, which can be aspirated into the lungs.
DISTINCTIVE DIAGNOSIS
Vincent's angina, viral pharyngitis, streptococcal pharyngitis, infectious mononucleosis, epiglottitis, infectious endocarditis, and herpes simplex virus
MEDICATION FOR TREATMENT
First Phrase
• Since horses produce diphtheria antitoxin (DAT) and patients may experience a hypersensitive reaction to horse antiserum, DAT should be given as soon as possible. With epinephrine and cardiac resuscitation resources nearby, a test dose is necessary.
• Antibiotics: Penicillin G 300,000 U/d for 14 days in patients under 10 kg i.m.
600,000 U/d for 14 days for patients weighing more than 10 kg i.m.
Erythromycin (for people who are allergic to penicillins) Adult: 500 mg intravenously every six hours for 14 days
Vancomycin for children: 40–50 mg/kg/day p.o./i.v., divided into 6 hourly doses for 14 days
Adult: given intravenously (1 g every 12 hours)
Children: intravenous infusion of 40 mg/kg/d over 1 hour, divided into 6 hourly doses; bronchodilators; antipyrexials; second-line pharmaceutical therapy as described above
ADDITIONAL MEDICATION
Overall Actions
Patients should be isolated as soon as possible. Two large-bore intravenous cannulae should be inserted. Cardiac monitoring should be done.
Referral issues include the following: anesthetist for airway management; surgery for surgical airway; cardiology for myocarditis; respiratory medication for bronchoscopy for pseudomembrane removal or obstruction; renal medication for acute tubular necrosis; and neurology for peripheral nerve damage.
ALTERNATIVE AND COMPLIMENTARY THERAPIES
Physiotherapy for neurological conditions
OTHER PROCEDURES AND SURGERY
Surgical airway may be necessary.
Considering the patient
First Stabilization
Provide patients with adequate resuscitation in accordance with pediatric basic life-support or advanced life support (ALS) procedures.
Requirements for Admission
Individuals with heart failure, septicemia, pulmonary compromise, or symptoms of infective endocarditis
IV fluids; aggressive fluid resuscitation in septic shock patients using colloids, such as Gelofusin
• When necessary, maintenance fluids containing Ringer's lactate
Until two nasopharyngeal swab cultures, obtained 24 and 48 hours after stopping antibiotics, are negative, nurses should isolate patients using universal and droplet precautions.
Criteria for Discharge
• Individuals with the two negative swabs mentioned above; • No indications of respiratory distress; • Stability of hemodynamics
Continuing Care Follow-Up Suggestions
Complete the age-appropriate immunization schedule; administer erythromycin or penicillin for 14 days to household members and close contacts; and get follow-up nasopharyngeal cultures to verify the eradication of bacteria.
DIET: Pasteurization is recommended for all dairy products.
PATIENT EDUCATION • Completing the age-appropriate immunization schedule is crucial • Seeking treatment as soon as an infection is suspected
Cardiac involvement is linked to a very poor prognosis.
prognosis; bacteremia mortality rates of 30–40%; high mortality rates in individuals under age 5 and those over age 40
Problems include: septicemia or septic shock; septic arthritis, osteomyelitis; myocarditis, cardiac dilatation and failure, mycotic aneurysm, endocarditis; cardiac rhythm abnormalities; secondary bacterial pneumonia; cranial nerve dysfunction, peripheral neuropathies, and complete paralysis; optic neuritis; acute tubular necrosis; and septicemia or septic shock. Five to ten percent of respiratory cases result in death.
- Published on
Infection Disease – Cytomegalovirus Infection
CYTOMEGALOVIRUS INFECTION
ESSENTIALS DESCRIPTION
A collection of cytomegalovirus-induced infections of various organs and systems (CMV)
The study of epidemiology
The prevalence
• An estimated 27,000 new CMV infections among seronegative pregnant women occur annually in the United States; the rate of infection among individuals aged 10–49 is estimated to be 1.6 infections per 100 susceptible persons annually.
Prevalence: CMV is a prevalent human infection that impacts individuals all over the world.
• Higher CMV seroprevalence is linked to older age and lower socioeconomic level.
• Among those above the age of six, the estimated CMV seroprevalence rate in the United States is 60%. Among people over 80, the seroprevalence could be as high as 90%.
RISK ELEMENTS
• •
Immunosuppression increases the risk of developing severe CMV infection symptoms.
Having a CMV mismatch status is the main risk factor for illness in transplant recipients.
When a CMV-seropositive donor (CMV D+/R-) gives an allograft to a CMV-seronegative recipient, this is known as a solid organ transplant (SOT).
When a patient of an allogeneic bone marrow transplant receives a graft from a donor who is CMV-seronegative (CMV D–/R+), there is an increased risk.
Transplant recipients of the pancreas, small intestine, and lung are most vulnerable to infection. Recipients of heart and liver transplants are at intermediate risk. Those who have kidney transplants are at the lowest risk.
application of substances that deplete lymphocytes (e.g., OKT3, anti-thymocyte globulins, and anti-lymphocyte globulin).
acute rejection of allografts. illness caused by graft versus host.
HIV infection with fewer than 50/mm3 CD4 count.
• • • •
OVERALL PREVENTION
• Prophylactic antiviral treatment for recipients with CMV mismatch or CMV seropositive status. A growing issue among CMV D+/R-patients who were given antiviral prophylaxis is late-onset CMV illness.
• Some facilities utilize CMV immunoglobulin to prevent illness in high-risk persons (those who have received intestine and lung transplants and have CMV D+/R).
It is recommended that recipients of CMV-seronegative allogeneic hematopoietic stem cell transplants (AI) receive blood products from CMV-seronegative donors or leukocyte-depleted blood products.
• CMV-related illnesses in HIV infection have significantly decreased as a result of highly active antiretroviral therapy (HAART).
• No vaccination is currently available.
Pathophysiology
• When a CMV-seronegative recipient receives an allograft from a CMV-seropositive donor (CMV D+/R–), primary CMV infection occurs in SOT recipients.
• Reactivation happens when a seropositive recipient's latent virus reactivates during immunosuppressive episodes. Because of pre-existing anti-CMV immunity, the disease is less severe.
• The infection can be categorized as either symptomatic (CMV illness) or asymptomatic (subclinical CMV infection).
• The disease is further subdivided into tissue-invasive disease (disease with end-organ involvement) and CMV syndrome (disease without end-organ involvement).
• End-organ disease poses a special risk to the transplanted organ.
ETIOLOGY
• The herpesvirus category includes the DNA virus known as CMV.
• Like other viruses in the herpes group, CMV can cause latent infection following primary infection.
COMMON CONNECTED CIRCUMSTANCES
AIDS; solid organ transplantation; bone marrow transplantation; and patients with leukemia or lymphoma, which are severe cancer-related cellular immune suppression
History of Diagnosis
• In immunocompetent individuals, CMV may cause an infectious mononucleosis-like illness or be asymptomatic.
• The symptoms of CMV syndrome include fever, malaise, arthralgias, and myalgias.
• The most prevalent end-organ disease is colitis, which manifests as diarrhea and abdominal pain.
• The symptoms of CMV gastritis include nausea, vomiting, and odynophagia.
• The symptoms of pneumonia include fever, coughing, and dyspnea.
• Hepatitis and myocarditis are further symptoms.
A progressive loss of visual acuity brought on by chorioretinitis can lead to blindness. Following the start of HAART, reports of immune reconstitution syndrome have been made.
Lethargy, photophobia, and a severe headache are symptoms of meningoencephalitis.
Most often, HIV-infected patients experience back discomfort with spinal cord involvement (myelitis, polyradiculitis).
MEDICAL EXAMINATION
Splenomegaly, lymphadenopathy, and pharyngitis
• Rubelliform and maculopapular rashes when CMV mononucleosis is present.
• Signs of encephalitis in the pyramidal tract.
• In myeloradiculopathy, descending weakness in the lower limbs accompanied by a loss of deep tendon reflexes.
• Funduscopic observations in cases of retinitis: Peripheral lesions develop into central ones. regions with perivascular exudates that are yellow-white. There could be bleeding.
Tests for Diagnosis and Interpretation
Lab
First laboratory testing
• Anemia, hemolytic anemia, or thrombocytopenia brought on by myelosuppression.
• Atypical lymphocytes are present.
• A positive CMV IgG serology is a sign of latent virus but also indicates antiviral immunity. beneficial for assessing transplant candidates prior to transplantation as well as possible donors.
• Acute CMV infection or reactivation may result in the presence of IgM antibodies against CMV.
Note: Since immunosuppressed individuals are unable to mount an immunological response, serology is usually not helpful in these cases.
• Viral nucleic acid detection and antigenemia assays are currently the recommended diagnostic methods due to their quick turnaround time and great sensitivity.
• There are numerous real-time PCR platforms (2).
• Tagled monoclonal antibodies specific to the CMV pp65 matrix protein in peripheral blood polymorphonuclear leukocytes are used in CMV antigenemia testing. Because leukocytes are absent in neutropenic patients, their usefulness is restricted.
• CMV has been isolated from blood or other bodily fluids or tissues using viral culture. After one to six weeks, cytotoxic effects appear.
• The shell vial assay is a variation of viral culture. Results are sent out in a day or two.
Follow-up and Particular Points to Remember
• After two weeks of full-dose treatment, if there are still clinical symptoms and a growing or non-declining viral load, consider a drug-resistant virus.
• It is possible to test for genotypic resistance:
UL97 phosphotransferase mutations cause decreased amounts of the active triphosphorylated substance cause ganciclovir resistance. Less frequently, UL54 DNA polymerase mutations happen as second-step alterations following exposure to cidofovir, foscarnet, or ganciclovir. may cause the three antiviral medications to become resistant to one another.
Imaging: CMV encephalitis: periventricular inflammation or meningeal enhancement on the brain; CMV colitis: thickening of the bowel wall on CT imaging; and CMV pneumonitis: interstitial infiltrates on plain radiography. MRI
Diagnostic Techniques and Other
• Colonoscopy in CMV colitis reveals mucosal erythema, erosions, ulcerations, bleeding, and nodular or polypoid lesions; bronchoscopy with bronchoalveolar lavage/biopsy in CMV pneumonitis
Pathological Results
• Tissue invasion is not always associated with CMV viremia. One way to show CMV in tissue is by histology, immunohistochemistry, or in situ DNA hybridization. Large intranuclear inclusions encircled by a transparent halo are common cytopathic findings. There may also be smaller cytoplasmic inclusions.
DIFFERENTIAL DIAGNOSIS
HIV infection (including abrupt seroconversion), human herpesvirus 6 infection, infectious mononucleosis, toxoplasmosis, viral hepatitis, viral gastroenteritis, cryptosporidiosis, and Clostridium difficile infection
MEDICAL CARE
• CMV syndrome typically resolves on its own in the immunocompetent host and doesn't require medical intervention.
• Antiviral medications should be used vigorously to treat CMV infections in immunocompromised patients.
MEDICATION
First Phrase
• The preferred treatment is ganciclovir (AII). Dosage for induction: 5 mg/kg intravenously twice a day. For renal failure, the dosage is modified.
For mild-to-moderate illness, valganciclovir 900 mg p.o. twice daily may be administered as an induction treatment (3).
• Following a first intravenous ganciclovir induction treatment, valganciclovir is often utilized as a step-down oral medication.
• In AIDS patients with CMV retinitis, a sustained-release intraocular ganciclovir implant combined with a systemic drug works better than intravenous treatment alone
Line Two
• For ganciclovir-resistant CMV, provide 60 mg/kg intravenously every 8 hours (or 90 mg/kg intravenously every 12 hours) of foscarnet.
For ganciclovir-resistant CMV, a weekly dosage of 5 mg/kg of cidofovir is recommended. If creatinine clearance is less than 55 mL/min, it is contraindicated.
• In cases of low-level ganciclovir resistance, higher doses of ganciclovir (7.5–10 mg/kg i.v. every 12 hours) have been utilized.
ADDITIONAL MEDICATION
Overall Actions
decrease in immunosuppressive medication dosages
Other Treatments
CMV immunoglobulin for pneumonitis (BIII), a severe form of CMV illness
Continuing Care Follow-Up Suggestions
Monitoring of Patients
• Following the start of antiviral therapy, it is beneficial to assess disease activity every week using molecular tests or antigenemia.
• Generally speaking, patients should be treated for at least two to four weeks, ideally until two weeks after their CMV viremia has cleared up. Recurrent illness is linked to a lack of clearance
• It has also been suggested that maintenance therapy, which involves giving antiviral medications at preventative dosages, be used to finish treatment, which typically lasts up to three months.
PROGNOSIS
• A CMV infection can be fatal, particularly in people with impaired immune systems.
• One of the most serious CMV infections, particularly in bone marrow transplant recipients, is pneumonia.
The fatality rate for CMV encephalitis is very significant.
COMPLICATIONS
• Bowel perforation and peritonitis can result with CMV colitis.
• Congestive cardiac failure can result from CMV myocarditis.
• Patients with HIV may experience cauda equina syndrome.
• Effects of indirect CMV on transplant recipients:
Chronic allograft failure and acute allograft rejection
In receivers with the lungs, bronchiolitis obliterans; in recipients with the heart, accelerated vasculopathy - In liver recipients, disappearing bile duct syndrome
Tubulo-interstitial fibrosis and glomerulopathy (in kidney recipients)
• After the decline in rubella incidence brought on by vaccination, congenital CMV infection is the leading cause of congenital abnormalities in developed nations.
• Abortion, fetal jaundice, anemia, and damage to the central nervous system can result from a congenital CMV infection.
CYTOMEGALOVIRUS INFECTION
ESSENTIALS DESCRIPTION
A collection of cytomegalovirus-induced infections of various organs and systems (CMV)
The study of epidemiology
The prevalence
• An estimated 27,000 new CMV infections among seronegative pregnant women occur annually in the United States; the rate of infection among individuals aged 10–49 is estimated to be 1.6 infections per 100 susceptible persons annually.
Prevalence: CMV is a prevalent human infection that impacts individuals all over the world.
• Higher CMV seroprevalence is linked to older age and lower socioeconomic level.
• Among those above the age of six, the estimated CMV seroprevalence rate in the United States is 60%. Among people over 80, the seroprevalence could be as high as 90%.
RISK ELEMENTS
• •
Immunosuppression increases the risk of developing severe CMV infection symptoms.
Having a CMV mismatch status is the main risk factor for illness in transplant recipients.
When a CMV-seropositive donor (CMV D+/R-) gives an allograft to a CMV-seronegative recipient, this is known as a solid organ transplant (SOT).
When a patient of an allogeneic bone marrow transplant receives a graft from a donor who is CMV-seronegative (CMV D–/R+), there is an increased risk.
Transplant recipients of the pancreas, small intestine, and lung are most vulnerable to infection. Recipients of heart and liver transplants are at intermediate risk. Those who have kidney transplants are at the lowest risk.
application of substances that deplete lymphocytes (e.g., OKT3, anti-thymocyte globulins, and anti-lymphocyte globulin).
acute rejection of allografts. illness caused by graft versus host.
HIV infection with fewer than 50/mm3 CD4 count.
• • • •
OVERALL PREVENTION
• Prophylactic antiviral treatment for recipients with CMV mismatch or CMV seropositive status. A growing issue among CMV D+/R-patients who were given antiviral prophylaxis is late-onset CMV illness.
• Some facilities utilize CMV immunoglobulin to prevent illness in high-risk persons (those who have received intestine and lung transplants and have CMV D+/R).
It is recommended that recipients of CMV-seronegative allogeneic hematopoietic stem cell transplants (AI) receive blood products from CMV-seronegative donors or leukocyte-depleted blood products.
• CMV-related illnesses in HIV infection have significantly decreased as a result of highly active antiretroviral therapy (HAART).
• No vaccination is currently available.
Pathophysiology
• When a CMV-seronegative recipient receives an allograft from a CMV-seropositive donor (CMV D+/R–), primary CMV infection occurs in SOT recipients.
• Reactivation happens when a seropositive recipient's latent virus reactivates during immunosuppressive episodes. Because of pre-existing anti-CMV immunity, the disease is less severe.
• The infection can be categorized as either symptomatic (CMV illness) or asymptomatic (subclinical CMV infection).
• The disease is further subdivided into tissue-invasive disease (disease with end-organ involvement) and CMV syndrome (disease without end-organ involvement).
• End-organ disease poses a special risk to the transplanted organ.
ETIOLOGY
• The herpesvirus category includes the DNA virus known as CMV.
• Like other viruses in the herpes group, CMV can cause latent infection following primary infection.
COMMON CONNECTED CIRCUMSTANCES
AIDS; solid organ transplantation; bone marrow transplantation; and patients with leukemia or lymphoma, which are severe cancer-related cellular immune suppression
History of Diagnosis
• In immunocompetent individuals, CMV may cause an infectious mononucleosis-like illness or be asymptomatic.
• The symptoms of CMV syndrome include fever, malaise, arthralgias, and myalgias.
• The most prevalent end-organ disease is colitis, which manifests as diarrhea and abdominal pain.
• The symptoms of CMV gastritis include nausea, vomiting, and odynophagia.
• The symptoms of pneumonia include fever, coughing, and dyspnea.
• Hepatitis and myocarditis are further symptoms.
A progressive loss of visual acuity brought on by chorioretinitis can lead to blindness. Following the start of HAART, reports of immune reconstitution syndrome have been made.
Lethargy, photophobia, and a severe headache are symptoms of meningoencephalitis.
Most often, HIV-infected patients experience back discomfort with spinal cord involvement (myelitis, polyradiculitis).
MEDICAL EXAMINATION
Splenomegaly, lymphadenopathy, and pharyngitis
• Rubelliform and maculopapular rashes when CMV mononucleosis is present.
• Signs of encephalitis in the pyramidal tract.
• In myeloradiculopathy, descending weakness in the lower limbs accompanied by a loss of deep tendon reflexes.
• Funduscopic observations in cases of retinitis: Peripheral lesions develop into central ones. regions with perivascular exudates that are yellow-white. There could be bleeding.
Tests for Diagnosis and Interpretation
Lab
First laboratory testing
• Anemia, hemolytic anemia, or thrombocytopenia brought on by myelosuppression.
• Atypical lymphocytes are present.
• A positive CMV IgG serology is a sign of latent virus but also indicates antiviral immunity. beneficial for assessing transplant candidates prior to transplantation as well as possible donors.
• Acute CMV infection or reactivation may result in the presence of IgM antibodies against CMV.
Note: Since immunosuppressed individuals are unable to mount an immunological response, serology is usually not helpful in these cases.
• Viral nucleic acid detection and antigenemia assays are currently the recommended diagnostic methods due to their quick turnaround time and great sensitivity.
• There are numerous real-time PCR platforms (2).
• Tagled monoclonal antibodies specific to the CMV pp65 matrix protein in peripheral blood polymorphonuclear leukocytes are used in CMV antigenemia testing. Because leukocytes are absent in neutropenic patients, their usefulness is restricted.
• CMV has been isolated from blood or other bodily fluids or tissues using viral culture. After one to six weeks, cytotoxic effects appear.
• The shell vial assay is a variation of viral culture. Results are sent out in a day or two.
Follow-up and Particular Points to Remember
• After two weeks of full-dose treatment, if there are still clinical symptoms and a growing or non-declining viral load, consider a drug-resistant virus.
• It is possible to test for genotypic resistance:
UL97 phosphotransferase mutations cause decreased amounts of the active triphosphorylated substance cause ganciclovir resistance. Less frequently, UL54 DNA polymerase mutations happen as second-step alterations following exposure to cidofovir, foscarnet, or ganciclovir. may cause the three antiviral medications to become resistant to one another.
Imaging: CMV encephalitis: periventricular inflammation or meningeal enhancement on the brain; CMV colitis: thickening of the bowel wall on CT imaging; and CMV pneumonitis: interstitial infiltrates on plain radiography. MRI
Diagnostic Techniques and Other
• Colonoscopy in CMV colitis reveals mucosal erythema, erosions, ulcerations, bleeding, and nodular or polypoid lesions; bronchoscopy with bronchoalveolar lavage/biopsy in CMV pneumonitis
Pathological Results
• Tissue invasion is not always associated with CMV viremia. One way to show CMV in tissue is by histology, immunohistochemistry, or in situ DNA hybridization. Large intranuclear inclusions encircled by a transparent halo are common cytopathic findings. There may also be smaller cytoplasmic inclusions.
DIFFERENTIAL DIAGNOSIS
HIV infection (including abrupt seroconversion), human herpesvirus 6 infection, infectious mononucleosis, toxoplasmosis, viral hepatitis, viral gastroenteritis, cryptosporidiosis, and Clostridium difficile infection
MEDICAL CARE
• CMV syndrome typically resolves on its own in the immunocompetent host and doesn't require medical intervention.
• Antiviral medications should be used vigorously to treat CMV infections in immunocompromised patients.
MEDICATION
First Phrase
• The preferred treatment is ganciclovir (AII). Dosage for induction: 5 mg/kg intravenously twice a day. For renal failure, the dosage is modified.
For mild-to-moderate illness, valganciclovir 900 mg p.o. twice daily may be administered as an induction treatment (3).
• Following a first intravenous ganciclovir induction treatment, valganciclovir is often utilized as a step-down oral medication.
• In AIDS patients with CMV retinitis, a sustained-release intraocular ganciclovir implant combined with a systemic drug works better than intravenous treatment alone
Line Two
• For ganciclovir-resistant CMV, provide 60 mg/kg intravenously every 8 hours (or 90 mg/kg intravenously every 12 hours) of foscarnet.
For ganciclovir-resistant CMV, a weekly dosage of 5 mg/kg of cidofovir is recommended. If creatinine clearance is less than 55 mL/min, it is contraindicated.
• In cases of low-level ganciclovir resistance, higher doses of ganciclovir (7.5–10 mg/kg i.v. every 12 hours) have been utilized.
ADDITIONAL MEDICATION
Overall Actions
decrease in immunosuppressive medication dosages
Other Treatments
CMV immunoglobulin for pneumonitis (BIII), a severe form of CMV illness
Continuing Care Follow-Up Suggestions
Monitoring of Patients
• Following the start of antiviral therapy, it is beneficial to assess disease activity every week using molecular tests or antigenemia.
• Generally speaking, patients should be treated for at least two to four weeks, ideally until two weeks after their CMV viremia has cleared up. Recurrent illness is linked to a lack of clearance
• It has also been suggested that maintenance therapy, which involves giving antiviral medications at preventative dosages, be used to finish treatment, which typically lasts up to three months.
PROGNOSIS
• A CMV infection can be fatal, particularly in people with impaired immune systems.
• One of the most serious CMV infections, particularly in bone marrow transplant recipients, is pneumonia.
The fatality rate for CMV encephalitis is very significant.
COMPLICATIONS
• Bowel perforation and peritonitis can result with CMV colitis.
• Congestive cardiac failure can result from CMV myocarditis.
• Patients with HIV may experience cauda equina syndrome.
• Effects of indirect CMV on transplant recipients:
Chronic allograft failure and acute allograft rejection
In receivers with the lungs, bronchiolitis obliterans; in recipients with the heart, accelerated vasculopathy - In liver recipients, disappearing bile duct syndrome
Tubulo-interstitial fibrosis and glomerulopathy (in kidney recipients)
• After the decline in rubella incidence brought on by vaccination, congenital CMV infection is the leading cause of congenital abnormalities in developed nations.
• Abortion, fetal jaundice, anemia, and damage to the central nervous system can result from a congenital CMV infection.
- Published on
Infectious Disease – Dengue
DENGUE
ESSENTIALS DESCRIPTION
A virus called dengue is spread by mosquitoes and causes a serious sickness that resembles the flu. With a 1–5% patient mortality rate, the virus can occasionally cause potentially fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
The study of epidemiology
The prevalence
• Two-fifths of the world's population, or over 2.5 billion people, are susceptible to infection
The rainy season increases transmission. An estimated 50–100 million infections, including 500,000 DHF cases and 22,000 fatalities, occur globally each year
The frequency
• The virus can be found in tropical regions and
It is endemic in around 100 nations in Asia, the Pacific, the Americas, Africa, and the Caribbean. It is found in subtropical zones, primarily in urban and suburban settings.
RISK ELEMENTS
Visiting or residing in dengue-endemic areas
Genetics
There are no hereditary elements at play.
GENERAL PREVENTION: Steer clear of mosquito bites and stay away from dengue endemic regions.
Wear long sleeves, ideally with permethrin insecticide impregnated. Apply mosquito repellent with at least 30% N,N-diethyl-3-methylbenzamide (DEET) on exposed skin and clothing.
– Because Aedes mosquitoes bite during the day, bed nets are not very effective.
• Vector control: Get rid of mosquitoes indoors by using insecticides; remove standing water from pools to get rid of mosquito breeding grounds.
Apply larvicidal compounds to sources of stagnant water, such as Abate.
Predatory copepods are introduced into stagnant water sources to control biological vectors.
Pathophysiology
• The incubation period for dengue after inoculation is 3–14 days, although it is often 4–7 days
• The virus replicates in dendritic cells; it then infects reticuloendothelial cells, including dendritic cells, hepatocytes, and endothelial cells; it releases immune mediators that influence cellular and humoral responses; the resulting acute febrile illness lasts 5–7 days; the patient recovers fully in 7–10 days; prior exposure to another dengue serotype predisposes the patient to DHF and DSS; and DHF and DSS typically appear between the third and seventh day of illness at the end of the febrile period. Capillary fragility, thrombocytopenia, and disseminated intravascular coagulation (DIC) cause hemorrhages ranging from minor petechiae to potentially fatal gastrointestinal (GI) bleeding; liver damage causes abnormal liver function tests; and increased capillary permeability causes plasma leakage, which leads to hemoconcentration and potential pleural effusions and ascites.
& coagulopathies • Hepatitis caused by Dengue can be lethal
ETIOLOGY The dengue virus belongs to the family Flaviviridae (ssRNA); it has four antigenically unique serotypes (types 1–4); the sole hosts of infection are humans and nonhuman primates; and Aedes mosquitoes, primarily Aedes aegypti and Aedes albopictus, are the vectors of transmission. Considerations for Children
There is evidence of mother-to-child transmission under COMMONLY ASSOCIATED CONDITIONS
History of Diagnosis
• Signs: fever, chills, headache, and myalgias Rash, bone pain following fever onset, nausea, vomiting, cutaneous hyperesthesia, altered taste perception, appetite loss, abdominal discomfort, and hemorrhagic symptoms such as bruising, epistaxis, gingival bleeding, gastrointestinal bleeding, and menorrhagia
• History of travel
PHYSICAL EXAMINATION • Fever • Shock symptoms, such as prolonged capillary refill, tachycardia, and hypotension • Rash: generalized blanching macular rash
Morbilliform maculopapular rash, which spares the palms and soles, is the second type of rash.
– Symptoms of bleeding include petechiae, purpura, epistaxis, gum bleeding, and gastrointestinal bleeding. In 97% of instances, conjunctival injection and pharyngeal injection are used.
Hepatomegaly, generalized lymphadenopathy, bleeding mucosae, and mental state assessment for changes in mental state brought on by encephalopathy—which is a result of cerebral edema and intracranial hemorrhages--
Tests for Diagnosis and Interpretation
Initial laboratory tests
IgG and IgM antibody serology (ELISA); complete blood count; leucopenia, frequently accompanied by lymphopenia; elevated hematocrit; thrombocytopenia; liver function tests; elevated transaminases; low albumin; and chemistry panel
Acidosis, elevated blood urea nitrogen (BUN), and hyponatremia
Low fibrinogen and high fibrin breakdown products in DIC; elevated prothrombin time (PT); elevated activated partial thromboplastin time (APTT); and coagulation screen
Currently unavailable in the clinical context are polymerase chain reaction (PCR) techniques; arterial blood gas in critically unwell patients
Follow-up and Particular Points to Remember
• When there is a significant bleeding, blood must be cross-matched. Blood and other bodily fluid cultures should be carried out as needed to rule out other potential causes of sickness.
Imagining
• Pleural effusion may be seen on a chest radiograph; ultrasound may be used to assess ascites, pericardial effusions, and pleural effusions as needed; CT scan of the head for individuals with altered mental states or low consciousness
Pathological Results
As mentioned in the first lab tests
DIFFERENTIAL DIAGNOSIS: Hepatitis, meningitis, leptospirosis, rickettsial disease, typhoid, malaria, yellow fever, bacterial sepsis, other viral infections (such as influenza, chikungunya, Rift Valley fever, and West Nile), bacterial sepsis, and pre-eclampsia during pregnancy
MEDICATION FOR TREATMENT
There is no particular treatment for DSS, DHF, or dengue fever.
ADDITIONAL MEDICATION
General Measures: • Adequate analgesics and antipyretics should be used; • Avoid aspirin because of the hemorrhagic character of the sickness; • Symptomatic and supportive therapy
Referral issues include: • Cardiologist for patients with pericardial effusions; • Critical care specialist for individuals with DHF or DSS; • Infectious disease specialist
Considering the patient
First Stabilization
Resuscitate using the advanced life support (ALS) protocol; administer oxygen empirically; use a large-bore intravenous catheter; administer intravenous colloids to maintain systolic blood pressure greater than 90 mm Hg; administer therapy for DIC if necessary; use an arterial line for continuous blood pressure monitoring and serial blood gas measurements if necessary; use a urethral catheter to measure urine output if necessary; reverse electrolyte abnormalities and acidosis; and cross-match blood in the event of a major bleeding incident secondary to DHF.
Requirements for Admission
Patients with hemodynamic instability; those with DHF or DSS; those who are hypotensive or in DIC should be admitted to intensive care units (ICUs); otherwise, they should be admitted to a general medicine ward.
IV fluids; fluids used in colloids for resuscitation, such as Gelofusine,
• Ringer's lactate maintenance fluids, such as dextran, hetastarch, and human albumin solution
For patients who are really sick, keep a tight fluid input-output log. Patients who are not awake may require frequent neuro-observations.
The patient must be hemodynamically stable and have preferably fully recovered from their sickness in order to be discharged.
Continuing Care Follow-Up Suggestions
• No particular advice for follow-up
Patients should be informed that they are more likely to develop DHF or DSS if they catch dengue of a different serotype. Cases should be reported to the Department of Public Health.
DIET: No particular diet is required. Promote the consumption of oral fluids.
Refer to the General Prevention Section on Patient Education.
PROGNOSIS: The majority of individuals with dengue fever recover completely, and the prognosis is excellent.
• Individuals who make it through the crucial phases of DSS and DHF
Neurological symptoms, brain damage from prolonged ischemia in shock or intracranial bleeding, encephalitis/encephalopathy, seizures, neuropathies, Guillain-Barré syndrome, transverse myelitis, myocarditis, and liver failure are among the conditions that typically resolve without any long-term effects.
DENGUE
ESSENTIALS DESCRIPTION
A virus called dengue is spread by mosquitoes and causes a serious sickness that resembles the flu. With a 1–5% patient mortality rate, the virus can occasionally cause potentially fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
The study of epidemiology
The prevalence
• Two-fifths of the world's population, or over 2.5 billion people, are susceptible to infection
The rainy season increases transmission. An estimated 50–100 million infections, including 500,000 DHF cases and 22,000 fatalities, occur globally each year
The frequency
• The virus can be found in tropical regions and
It is endemic in around 100 nations in Asia, the Pacific, the Americas, Africa, and the Caribbean. It is found in subtropical zones, primarily in urban and suburban settings.
RISK ELEMENTS
Visiting or residing in dengue-endemic areas
Genetics
There are no hereditary elements at play.
GENERAL PREVENTION: Steer clear of mosquito bites and stay away from dengue endemic regions.
Wear long sleeves, ideally with permethrin insecticide impregnated. Apply mosquito repellent with at least 30% N,N-diethyl-3-methylbenzamide (DEET) on exposed skin and clothing.
– Because Aedes mosquitoes bite during the day, bed nets are not very effective.
• Vector control: Get rid of mosquitoes indoors by using insecticides; remove standing water from pools to get rid of mosquito breeding grounds.
Apply larvicidal compounds to sources of stagnant water, such as Abate.
Predatory copepods are introduced into stagnant water sources to control biological vectors.
Pathophysiology
• The incubation period for dengue after inoculation is 3–14 days, although it is often 4–7 days
• The virus replicates in dendritic cells; it then infects reticuloendothelial cells, including dendritic cells, hepatocytes, and endothelial cells; it releases immune mediators that influence cellular and humoral responses; the resulting acute febrile illness lasts 5–7 days; the patient recovers fully in 7–10 days; prior exposure to another dengue serotype predisposes the patient to DHF and DSS; and DHF and DSS typically appear between the third and seventh day of illness at the end of the febrile period. Capillary fragility, thrombocytopenia, and disseminated intravascular coagulation (DIC) cause hemorrhages ranging from minor petechiae to potentially fatal gastrointestinal (GI) bleeding; liver damage causes abnormal liver function tests; and increased capillary permeability causes plasma leakage, which leads to hemoconcentration and potential pleural effusions and ascites.
& coagulopathies • Hepatitis caused by Dengue can be lethal
ETIOLOGY The dengue virus belongs to the family Flaviviridae (ssRNA); it has four antigenically unique serotypes (types 1–4); the sole hosts of infection are humans and nonhuman primates; and Aedes mosquitoes, primarily Aedes aegypti and Aedes albopictus, are the vectors of transmission. Considerations for Children
There is evidence of mother-to-child transmission under COMMONLY ASSOCIATED CONDITIONS
History of Diagnosis
• Signs: fever, chills, headache, and myalgias Rash, bone pain following fever onset, nausea, vomiting, cutaneous hyperesthesia, altered taste perception, appetite loss, abdominal discomfort, and hemorrhagic symptoms such as bruising, epistaxis, gingival bleeding, gastrointestinal bleeding, and menorrhagia
• History of travel
PHYSICAL EXAMINATION • Fever • Shock symptoms, such as prolonged capillary refill, tachycardia, and hypotension • Rash: generalized blanching macular rash
Morbilliform maculopapular rash, which spares the palms and soles, is the second type of rash.
– Symptoms of bleeding include petechiae, purpura, epistaxis, gum bleeding, and gastrointestinal bleeding. In 97% of instances, conjunctival injection and pharyngeal injection are used.
Hepatomegaly, generalized lymphadenopathy, bleeding mucosae, and mental state assessment for changes in mental state brought on by encephalopathy—which is a result of cerebral edema and intracranial hemorrhages--
Tests for Diagnosis and Interpretation
Initial laboratory tests
IgG and IgM antibody serology (ELISA); complete blood count; leucopenia, frequently accompanied by lymphopenia; elevated hematocrit; thrombocytopenia; liver function tests; elevated transaminases; low albumin; and chemistry panel
Acidosis, elevated blood urea nitrogen (BUN), and hyponatremia
Low fibrinogen and high fibrin breakdown products in DIC; elevated prothrombin time (PT); elevated activated partial thromboplastin time (APTT); and coagulation screen
Currently unavailable in the clinical context are polymerase chain reaction (PCR) techniques; arterial blood gas in critically unwell patients
Follow-up and Particular Points to Remember
• When there is a significant bleeding, blood must be cross-matched. Blood and other bodily fluid cultures should be carried out as needed to rule out other potential causes of sickness.
Imagining
• Pleural effusion may be seen on a chest radiograph; ultrasound may be used to assess ascites, pericardial effusions, and pleural effusions as needed; CT scan of the head for individuals with altered mental states or low consciousness
Pathological Results
As mentioned in the first lab tests
DIFFERENTIAL DIAGNOSIS: Hepatitis, meningitis, leptospirosis, rickettsial disease, typhoid, malaria, yellow fever, bacterial sepsis, other viral infections (such as influenza, chikungunya, Rift Valley fever, and West Nile), bacterial sepsis, and pre-eclampsia during pregnancy
MEDICATION FOR TREATMENT
There is no particular treatment for DSS, DHF, or dengue fever.
ADDITIONAL MEDICATION
General Measures: • Adequate analgesics and antipyretics should be used; • Avoid aspirin because of the hemorrhagic character of the sickness; • Symptomatic and supportive therapy
Referral issues include: • Cardiologist for patients with pericardial effusions; • Critical care specialist for individuals with DHF or DSS; • Infectious disease specialist
Considering the patient
First Stabilization
Resuscitate using the advanced life support (ALS) protocol; administer oxygen empirically; use a large-bore intravenous catheter; administer intravenous colloids to maintain systolic blood pressure greater than 90 mm Hg; administer therapy for DIC if necessary; use an arterial line for continuous blood pressure monitoring and serial blood gas measurements if necessary; use a urethral catheter to measure urine output if necessary; reverse electrolyte abnormalities and acidosis; and cross-match blood in the event of a major bleeding incident secondary to DHF.
Requirements for Admission
Patients with hemodynamic instability; those with DHF or DSS; those who are hypotensive or in DIC should be admitted to intensive care units (ICUs); otherwise, they should be admitted to a general medicine ward.
IV fluids; fluids used in colloids for resuscitation, such as Gelofusine,
• Ringer's lactate maintenance fluids, such as dextran, hetastarch, and human albumin solution
For patients who are really sick, keep a tight fluid input-output log. Patients who are not awake may require frequent neuro-observations.
The patient must be hemodynamically stable and have preferably fully recovered from their sickness in order to be discharged.
Continuing Care Follow-Up Suggestions
• No particular advice for follow-up
Patients should be informed that they are more likely to develop DHF or DSS if they catch dengue of a different serotype. Cases should be reported to the Department of Public Health.
DIET: No particular diet is required. Promote the consumption of oral fluids.
Refer to the General Prevention Section on Patient Education.
PROGNOSIS: The majority of individuals with dengue fever recover completely, and the prognosis is excellent.
• Individuals who make it through the crucial phases of DSS and DHF
Neurological symptoms, brain damage from prolonged ischemia in shock or intracranial bleeding, encephalitis/encephalopathy, seizures, neuropathies, Guillain-Barré syndrome, transverse myelitis, myocarditis, and liver failure are among the conditions that typically resolve without any long-term effects.
- Published on
Infectious Disease - Cystitis
CYSTITIS
ESSENTIALS DESCRIPTION
Both men and women can get cystitis, a lower urinary tract infection (UTI) that affects the bladder.
The study of epidemiology
The prevalence
• In the US, there are 7 million UTI cases each year.
• Roughly one-third of women aged 24 and older will experience at least one UTI episode that necessitates antibiotic therapy (1).
• Within the first year, around half of the women whose simple UTIs go away on their own will get another UTI (2).
The frequency
more common in young women (20% vs. 0.5%, respectively, ages 16–35) than in young men.
RISK FACTORS • Premenopausal women: spermicide use, diaphragm contraception, increasing parity, diabetes mellitus, pregnancy, obesity, neurologic diseases, history of urinary tract infections, anatomic congenital abnormalities, frequent or recent sexual activity, and medical conditions requiring indwelling or repetitive bladder catheterization (3).
UTI history, vaginal atrophy, inadequate bladder emptying, rectocele, cystocele, urethrocele, uterovaginal prolapse, and type 1 diabetes are all present in postmenopausal women (3).
Men: incontinence, surgery, catheterization, urethral blockage, and prostate hypertrophy.
•
For general prevention, practice good atomic hygiene, refrain from using diaphragms, get regular urine tests in the third trimester of pregnancy, and avoid glycosuria if you have diabetes.
ETIOLOGY • The most frequent cause (~>80%) is Escherichia coli.
Proteus mirabilis, Enterobacter species, Citrobacter species, Serratia species, Klebsiella species, Salmonella species, and Morganella morganii are examples of other Enterobacteriaceae. Pseudomonas aeruginosa is an example of a non-Enterobacteriaceae species.
• Another significant issue is the rise of uropathogens, primarily E. coli, that cause nosocomial and community-acquired cystitis and have a notably high level of resistance because they produce extended-spectrum -lactamases (ESBLs) (4). • Saprophyticus Staphylococcus
History of Diagnosis
• Ten percent of patients have low back discomfort, suprapubic tenderness, murky urine, sudden onset, frequency, urgency, and occasionally bloody or foul-smelling urine.
• Kids: General symptoms (diarrhea, vomiting, fever, etc.)
• Older adults: Few symptoms
MEDICAL EXAMINATION
Tenderness in the suprapubic region
Tests for Diagnosis and Interpretation Lab
Urine microscopy, urine culture, and urinary dipstick testing (which detects nitrites and leukocyte esterase in the urine)
• Examine if a pregnancy test is required.
Imagining
• Male ultrasound
• If a young woman experiences recurrent episodes unrelated to coitus or does not respond to antibiotic treatment (as indicated by in vitro antibiotic susceptibility data), consider ultrasonography.
Diagnostic Techniques and Other
Urodynamic examination. Nevertheless, there is little evidence to support the claim that urodynamic testing is helpful in identifying particular urogynecologic mechanisms that would have helped prevent or enhance the medicinal and/or surgical treatment of recurrent UTIs (5).
• Bladder biopsies, cystoscopy, and urography. However, the usefulness of cystoscopy can be regarded as somewhat limited because patients with cystitis rarely experience morphological and/or functional abnormalities of the urinary system (6).
• x-rays of the bladder
DISTINCTIVE DIAGNOSIS
• Contagious: urethritis, vaginitis, silent bacteriuria, and pyelonephritis (upper UTI).
Interstitial cystitis, urolithiasis, bladder tumors, and chronic prostatitis/chronic pelvic pain syndrome are examples of noninfectious conditions.
MEDICATION FOR TREATMENT
Cystitis Recurrent
It has been proposed that a 95% reduction in the risk of recurrence can be achieved by continuous prophylaxis with once-daily treatment with norfloxacin, ciprofloxacin, trimethoprim (TMP), trimethoprim–sulfamethoxazole (TMP-SMX), or nitrofurantoin (8). However, such a strategy needs to be tailored in this day and age due to the startlingly high levels of antibiotic resistance in uropathogens.
Acute Uncomplicated Cystitis • Oral twice daily for three days of trimethoprim-sulfamethoxazole (TMP-SMX): TMP: 160 mg-SMX: 800 mg
• Ciprofloxacin: 250 mg twice daily for three days; Levofloxacin: 250 mg once daily for three days; Norfloxacin: 400 mg twice daily for three days; TMP: 100 mg twice daily for three days; and Fosfomycin tromethamine: 3 g oral single dose (3,7)
• Nitrofurantoin macrocrystals: four times a day, 50–100 mg
for seven days
• 100 mg twice a day for seven days of nitrofurantoin monohydrate macrocrystals (3) Considerations for Pregnancy
For three days, take 250 mg of amoxicillin every eight hours, 100 mg of microcrystalline nitrofurantoin four times a day, and 200 mg of cefpodoxime twice a day. Because it may cause hemolysis in the fetus or newborn, avoid administering it during labor or obstetric delivery as well as in late pregnancy (38–42 weeks). Given that adverse effects appear to be substantially less common in pregnant women treated with fosfomycin than in those treated with other antibiotics, fosfomycin may also be useful in the treatment of cystitis during pregnancy (7).
COMPLEMENTARY & ALTERNATIVE THERAPIES • Probiotics: Studies have demonstrated that Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are the most effective lactobacilli for preventing urinary tract infections. Significant effectiveness has also been demonstrated by L. crispatus CTV-05 and L. casei shirota. On the
However, it has been demonstrated that L. rhamnosus GG is not as successful in preventing UTIs (9).
• Cranberry juice: It may help treat and/or prevent UTIs because it has been proposed to be a strong inhibitor of bacterial adhesion (10). In example, cranberry juice has been shown to have the potential to lower the number of symptomatic UTIs over a 12-month period, especially for women who experience recurrent UTIs (11).
• Methenamine salts (methenamine hippurate): In individuals without urinary tract abnormalities, methenamine hippurate medication for a brief period of time (≤1 week) has been linked to a significant decrease in symptomatic UTI. Nevertheless, patients with neuropathic bladder or urinary tract disorders do not seem to benefit from them (12).
• Uroanalgesics: The goal of giving uroanalgesics, like phenazopyridine, to individuals who are experiencing acute cystitis symptoms is to alleviate their symptoms. The mucosa of the bladder may experience analgesia from phenazopyridine. Additionally, it has been proposed that its antibacterial action is increased when administered in conjunction with sulfonamides (13). Nonetheless, numerous research indicated that phenazopyridine can be linked to negative side effects, such as
anemia due to hemolysis (14).
• There is still inadequate data to support the idea that intensive hydration can effectively avoid recurrent cystitis.
• There is also mixed evidence about the efficacy of oral and vaginal exogenous estrogens in preventing recurrent UTIs in postmenopausal women (15).
OTHER PROCEDURES AND SURGERY
Surgical correction of urinary tract anatomical defects
PROGNOSIS FOR ONGOING CARE: Most patients with acute, uncomplicated cystitis have a very good prognosis with proper antibiotic treatment.
• Nevertheless, patients without complications or those with risk factors (such anomalies of the urinary system) may experience recurrent cystitis.
Pyelonephritis, urethritis, and mental illnesses, especially following recurrent cystitis
CYSTITIS
ESSENTIALS DESCRIPTION
Both men and women can get cystitis, a lower urinary tract infection (UTI) that affects the bladder.
The study of epidemiology
The prevalence
• In the US, there are 7 million UTI cases each year.
• Roughly one-third of women aged 24 and older will experience at least one UTI episode that necessitates antibiotic therapy (1).
• Within the first year, around half of the women whose simple UTIs go away on their own will get another UTI (2).
The frequency
more common in young women (20% vs. 0.5%, respectively, ages 16–35) than in young men.
RISK FACTORS • Premenopausal women: spermicide use, diaphragm contraception, increasing parity, diabetes mellitus, pregnancy, obesity, neurologic diseases, history of urinary tract infections, anatomic congenital abnormalities, frequent or recent sexual activity, and medical conditions requiring indwelling or repetitive bladder catheterization (3).
UTI history, vaginal atrophy, inadequate bladder emptying, rectocele, cystocele, urethrocele, uterovaginal prolapse, and type 1 diabetes are all present in postmenopausal women (3).
Men: incontinence, surgery, catheterization, urethral blockage, and prostate hypertrophy.
•
For general prevention, practice good atomic hygiene, refrain from using diaphragms, get regular urine tests in the third trimester of pregnancy, and avoid glycosuria if you have diabetes.
ETIOLOGY • The most frequent cause (~>80%) is Escherichia coli.
Proteus mirabilis, Enterobacter species, Citrobacter species, Serratia species, Klebsiella species, Salmonella species, and Morganella morganii are examples of other Enterobacteriaceae. Pseudomonas aeruginosa is an example of a non-Enterobacteriaceae species.
• Another significant issue is the rise of uropathogens, primarily E. coli, that cause nosocomial and community-acquired cystitis and have a notably high level of resistance because they produce extended-spectrum -lactamases (ESBLs) (4). • Saprophyticus Staphylococcus
History of Diagnosis
• Ten percent of patients have low back discomfort, suprapubic tenderness, murky urine, sudden onset, frequency, urgency, and occasionally bloody or foul-smelling urine.
• Kids: General symptoms (diarrhea, vomiting, fever, etc.)
• Older adults: Few symptoms
MEDICAL EXAMINATION
Tenderness in the suprapubic region
Tests for Diagnosis and Interpretation Lab
Urine microscopy, urine culture, and urinary dipstick testing (which detects nitrites and leukocyte esterase in the urine)
• Examine if a pregnancy test is required.
Imagining
• Male ultrasound
• If a young woman experiences recurrent episodes unrelated to coitus or does not respond to antibiotic treatment (as indicated by in vitro antibiotic susceptibility data), consider ultrasonography.
Diagnostic Techniques and Other
Urodynamic examination. Nevertheless, there is little evidence to support the claim that urodynamic testing is helpful in identifying particular urogynecologic mechanisms that would have helped prevent or enhance the medicinal and/or surgical treatment of recurrent UTIs (5).
• Bladder biopsies, cystoscopy, and urography. However, the usefulness of cystoscopy can be regarded as somewhat limited because patients with cystitis rarely experience morphological and/or functional abnormalities of the urinary system (6).
• x-rays of the bladder
DISTINCTIVE DIAGNOSIS
• Contagious: urethritis, vaginitis, silent bacteriuria, and pyelonephritis (upper UTI).
Interstitial cystitis, urolithiasis, bladder tumors, and chronic prostatitis/chronic pelvic pain syndrome are examples of noninfectious conditions.
MEDICATION FOR TREATMENT
Cystitis Recurrent
It has been proposed that a 95% reduction in the risk of recurrence can be achieved by continuous prophylaxis with once-daily treatment with norfloxacin, ciprofloxacin, trimethoprim (TMP), trimethoprim–sulfamethoxazole (TMP-SMX), or nitrofurantoin (8). However, such a strategy needs to be tailored in this day and age due to the startlingly high levels of antibiotic resistance in uropathogens.
Acute Uncomplicated Cystitis • Oral twice daily for three days of trimethoprim-sulfamethoxazole (TMP-SMX): TMP: 160 mg-SMX: 800 mg
• Ciprofloxacin: 250 mg twice daily for three days; Levofloxacin: 250 mg once daily for three days; Norfloxacin: 400 mg twice daily for three days; TMP: 100 mg twice daily for three days; and Fosfomycin tromethamine: 3 g oral single dose (3,7)
• Nitrofurantoin macrocrystals: four times a day, 50–100 mg
for seven days
• 100 mg twice a day for seven days of nitrofurantoin monohydrate macrocrystals (3) Considerations for Pregnancy
For three days, take 250 mg of amoxicillin every eight hours, 100 mg of microcrystalline nitrofurantoin four times a day, and 200 mg of cefpodoxime twice a day. Because it may cause hemolysis in the fetus or newborn, avoid administering it during labor or obstetric delivery as well as in late pregnancy (38–42 weeks). Given that adverse effects appear to be substantially less common in pregnant women treated with fosfomycin than in those treated with other antibiotics, fosfomycin may also be useful in the treatment of cystitis during pregnancy (7).
COMPLEMENTARY & ALTERNATIVE THERAPIES • Probiotics: Studies have demonstrated that Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are the most effective lactobacilli for preventing urinary tract infections. Significant effectiveness has also been demonstrated by L. crispatus CTV-05 and L. casei shirota. On the
However, it has been demonstrated that L. rhamnosus GG is not as successful in preventing UTIs (9).
• Cranberry juice: It may help treat and/or prevent UTIs because it has been proposed to be a strong inhibitor of bacterial adhesion (10). In example, cranberry juice has been shown to have the potential to lower the number of symptomatic UTIs over a 12-month period, especially for women who experience recurrent UTIs (11).
• Methenamine salts (methenamine hippurate): In individuals without urinary tract abnormalities, methenamine hippurate medication for a brief period of time (≤1 week) has been linked to a significant decrease in symptomatic UTI. Nevertheless, patients with neuropathic bladder or urinary tract disorders do not seem to benefit from them (12).
• Uroanalgesics: The goal of giving uroanalgesics, like phenazopyridine, to individuals who are experiencing acute cystitis symptoms is to alleviate their symptoms. The mucosa of the bladder may experience analgesia from phenazopyridine. Additionally, it has been proposed that its antibacterial action is increased when administered in conjunction with sulfonamides (13). Nonetheless, numerous research indicated that phenazopyridine can be linked to negative side effects, such as
anemia due to hemolysis (14).
• There is still inadequate data to support the idea that intensive hydration can effectively avoid recurrent cystitis.
• There is also mixed evidence about the efficacy of oral and vaginal exogenous estrogens in preventing recurrent UTIs in postmenopausal women (15).
OTHER PROCEDURES AND SURGERY
Surgical correction of urinary tract anatomical defects
PROGNOSIS FOR ONGOING CARE: Most patients with acute, uncomplicated cystitis have a very good prognosis with proper antibiotic treatment.
• Nevertheless, patients without complications or those with risk factors (such anomalies of the urinary system) may experience recurrent cystitis.
Pyelonephritis, urethritis, and mental illnesses, especially following recurrent cystitis
- Published on
Infectious Disease - Cysticercosis
CYSTICERCOSIS
BASICS DESCRIPTION
Taenia solium larvae, which cause cysticercosis, are parasitic infections
• When larvae travel to striated muscle, subcutaneous tissue, and other tissues and critical organs of the body, they develop characteristic cysts (cysticerci), which result in clinical symptoms.
• Many infections are asymptomatic; the most often impacted organs are the skin, heart, skeletal muscle, eyes, and central nervous system (CNS) (neurocysticercosis).
The study of epidemiology
The prevalence
• The most prevalent parasite that causes CNS illness is T. solium.
• In developing nations, it is the leading cause of seizures.
• Up to 10% of all computed tomography (CT) scans in Mexico
Neurocysticercosis is evident on scans at certain institutions.
The frequency
• Globally, more than 50 million persons are infected
• Eastern Europe, Southeast Asia, India, Central and South America, and sub-Saharan Africa have the highest prevalences.
• At least 10% of endemic villages had seropositive results for infection (2).
• In endemic communities, adult T. solium worms may be present in up to 6% of the population at any given time.
RISK ELEMENTS
• Consuming pork that is undercooked or uncooked
• Residencing in unsanitary regions
• Residencing in pig-populated areas, particularly those where pigs have access to human waste
• Inadequate hand hygiene that results in oral and fecal infections (1–5)
Genetics
There are no hereditary elements at play.
OVERALL PREVENTION
• Health education; • Prevent fecal contamination of water, land, and food for humans and animals; • Thoroughly cook pork; Cysticerci are killed when pork is frozen below -5°C (23°F) for longer than four days.
Personal cleanliness and sanitary food preparation
Family members should be screened for illness; cases should be identified and treated right away or in large quantities; pig populations should be treated concurrently; hand washing should be practiced; cleanliness should be improved; strict meat inspection should be followed; and contaminated carcasses should be disposed of properly.
PATHOPHYSIOLOGY: Humans become hosts when they consume T. solium eggs. • Cysticerci grow inside organs and tissue.
• Neurocysticercosis : The majority of neurological symptoms are brought on by immune-mediated inflammation brought on by degenerating cysts. Cysticerci either occupy space or obstruct the flow of cerebrospinal fluid, which results in mass effect symptoms.
• Extraneural cysticercosis: Ocular cysts can develop in the subretinal area, although they typically occur in the vitreous fluid. Damage to retinal tissue or the onset of chronic uveitis are linked to visual impairment.
Skin cysticerci appear as subcutaneous nodules. Nodules may become irritated and painful.
– Although skeletal muscle cysts typically don't cause any symptoms, a high parasite burden can lead to muscular pseudohypertrophy.
– Conduction problems may result from cardiac muscle cysts.
ETIOLOGY
• Human small intestines are the definitive host for adult tapeworms
• Gravid proglottids or eggs are expelled by humans in their stool. – Both male and female reproductive organs are found in proglottids, which are segments of tapeworms. There are 50–60 × 103 viable eggs in each segment.
• The eggs are consumed by the pig, which serves as the intermediate host, and the larvae develop. The pig's bloodstream carries the larvae, which reach elevated concentrations in their muscle.
• When undercooked pork (muscle) is consumed, the head ejaculates and adheres to the new host's intestinal wall. A classic intestinal tapeworm infection results from this.
– The adult T. solium's lifespan is unknown. estimated to be between five and thirty years.
• When humans consume eggs discharged in their feces, they acquire cysticercosis, which is caused by the larval stages.
• The oncospheres that form from the eggs pass through the small intestine.
• Ingestion of eggs might come from another source or as an autoinfection in a patient who already has tapeworm.
COMMON CONNECTED CIRCUMSTANCES
• Strokes, hydrocephalus, epilepsy, and intracranial hypertension
History of Diagnosis
• Sleeplessness, anorexia, and weight loss are among the disease's symptoms.
Pain in the abdomen
Disorders of the digestive system A persistent headache
Seizures, nausea, and vomiting
Neurological symptoms that are focal
Changes in mental state; visual abnormalities or eyesight changes; and skin nodules
Living in or traveling to regions where cysticercosis is widespread; interacting with individuals who have the disease; eating undercooked ham; and asking about worm segments excreted
PHYSICAL EXAMINATION
The following are examples of physical findings:
Fever absence; typically nonfocal neurologic symptoms
The presence of intraocular larvae on ophthalmoscopy may be diagnostic, as can papilledema and reduced retinal venous pulsations.
Meningitis
Visual impairments or nystagmus; hyperreflexia
Sebaceous cyst-like subcutaneous nodules that are palpable
The pseudohypertrophy of muscles
Tests for Diagnosis and Interpretation
Lab
• Serology-full blood count; frequently missing eosinophilia
The enzyme-linked immunosorbent test is very specific and has a 74% sensitivity. As the number of cysts increases, so does sensitivity.
In patients with numerous cysts, the enzyme-linked immunoelectrotransfer blot has a sensitivity of >95% and a specificity of over 100%. Patients with a solitary cyst are poor.
Stool for parasites and ova.
Imaging techniques include soft tissue x-rays, which can reveal calcified cysts, brain CT scans, and brain MRIs, which are the preferred imaging method for detecting brainstem cysts.
Diagnostic Techniques and Other
Both lumbar puncture and biopsy or fine-needle aspiration of subcutaneous nodules are not sensitive or specific. Cerebrospinal fluid may exhibit lymphocytosis, elevated protein, and/or decreased glucose levels when there is severe inflammation.
Pathological Results
Cysts range in size from a few millimeters to 1-2 centimeters and are uniformly round or oval vesicles.
Differential diagnosis, brain tumors, brain abscess, and status epilepticus
These include encephalitis, epidural and subdural infections, meningitis, tuberculosis, hemorrhagic and ischemic strokes, subarachnoid hemorrhage, endophthalmitis, migraine, tension headaches, coccidioidomycosis, toxoplasmosis, and trichomoniasis.
MEDICATION FOR TREATMENT
First Line • Corticosteroids: Prednisone orally or dexamethasone intravenously • Anticonvulsants: Lorazepam, phenytoin, or phenobarbital • Anthelmintics (2): Praziquantel 50 mg/kg/d orally in three divided doses each day for two weeks
For two weeks, take two to three divided doses of second line albendazole (15 mg/kg/d) orally.
ADDITIONAL MEDICATION
Referral issues: • A referral to a neurologist
Seizures, changes in mental status, and other neurological symptoms
Referral to a neurosurgeon for surgical intervention to lower intracranial pressure; Referral to an ophthalmologist for changes in vision or visual problems
OTHER PROCEDURES AND SURGERY
• Interventricular shunt • Ventriculoperitoneal shunt
IN-PATIENT CONSIDERATIONS
• Burr hole to reduce intracranial pressure
First Stabilization
As needed, resuscitation in accordance with the Acute Life Support procedure
Requirements for Admission
• For IV corticosteroid therapy to lower intracranial pressure in patients with status epilepticus
• For patients needing ocular surgery
• For surgical procedures to lower intracranial pressure from obstructive hydrocephalus
Intravenous Fluids
Fluids used for maintenance that contain Ringers lactate
Nursing
Employ the proper barrier nursing strategies.
Criteria for Discharge
• Seizures are stopped; the patient is clinically stable
Continuing Care Follow-Up Suggestions
For patients with chronic CNS calcifications, long-term anticonvulsant treatment
Monitoring of Patients
MRI or follow-up CT scan to evaluate therapy response
A DIET
Before eating, pork should be cooked through.
PATIENT EDUCATION: As mentioned in "General Prevention," patients and their families should understand how to treat seizures with first aid; how to take prescribed drugs; and when to seek medical attention, particularly when to look for symptoms of elevated intracranial pressure or localized
neurologic complaints: People who have recently experienced seizures shouldn't drive, use heavy equipment, climb ladders, swim, or engage in other risky activities.
PROGNOSIS
With the right diagnosis and care, the prognosis is typically excellent.
problems include: loss of eyesight; status epilepticus; stroke; intracranial herniation; long-term anticonvulsant use; and intraventricular shunt problems.
CYSTICERCOSIS
BASICS DESCRIPTION
Taenia solium larvae, which cause cysticercosis, are parasitic infections
• When larvae travel to striated muscle, subcutaneous tissue, and other tissues and critical organs of the body, they develop characteristic cysts (cysticerci), which result in clinical symptoms.
• Many infections are asymptomatic; the most often impacted organs are the skin, heart, skeletal muscle, eyes, and central nervous system (CNS) (neurocysticercosis).
The study of epidemiology
The prevalence
• The most prevalent parasite that causes CNS illness is T. solium.
• In developing nations, it is the leading cause of seizures.
• Up to 10% of all computed tomography (CT) scans in Mexico
Neurocysticercosis is evident on scans at certain institutions.
The frequency
• Globally, more than 50 million persons are infected
• Eastern Europe, Southeast Asia, India, Central and South America, and sub-Saharan Africa have the highest prevalences.
• At least 10% of endemic villages had seropositive results for infection (2).
• In endemic communities, adult T. solium worms may be present in up to 6% of the population at any given time.
RISK ELEMENTS
• Consuming pork that is undercooked or uncooked
• Residencing in unsanitary regions
• Residencing in pig-populated areas, particularly those where pigs have access to human waste
• Inadequate hand hygiene that results in oral and fecal infections (1–5)
Genetics
There are no hereditary elements at play.
OVERALL PREVENTION
• Health education; • Prevent fecal contamination of water, land, and food for humans and animals; • Thoroughly cook pork; Cysticerci are killed when pork is frozen below -5°C (23°F) for longer than four days.
Personal cleanliness and sanitary food preparation
Family members should be screened for illness; cases should be identified and treated right away or in large quantities; pig populations should be treated concurrently; hand washing should be practiced; cleanliness should be improved; strict meat inspection should be followed; and contaminated carcasses should be disposed of properly.
PATHOPHYSIOLOGY: Humans become hosts when they consume T. solium eggs. • Cysticerci grow inside organs and tissue.
• Neurocysticercosis : The majority of neurological symptoms are brought on by immune-mediated inflammation brought on by degenerating cysts. Cysticerci either occupy space or obstruct the flow of cerebrospinal fluid, which results in mass effect symptoms.
• Extraneural cysticercosis: Ocular cysts can develop in the subretinal area, although they typically occur in the vitreous fluid. Damage to retinal tissue or the onset of chronic uveitis are linked to visual impairment.
Skin cysticerci appear as subcutaneous nodules. Nodules may become irritated and painful.
– Although skeletal muscle cysts typically don't cause any symptoms, a high parasite burden can lead to muscular pseudohypertrophy.
– Conduction problems may result from cardiac muscle cysts.
ETIOLOGY
• Human small intestines are the definitive host for adult tapeworms
• Gravid proglottids or eggs are expelled by humans in their stool. – Both male and female reproductive organs are found in proglottids, which are segments of tapeworms. There are 50–60 × 103 viable eggs in each segment.
• The eggs are consumed by the pig, which serves as the intermediate host, and the larvae develop. The pig's bloodstream carries the larvae, which reach elevated concentrations in their muscle.
• When undercooked pork (muscle) is consumed, the head ejaculates and adheres to the new host's intestinal wall. A classic intestinal tapeworm infection results from this.
– The adult T. solium's lifespan is unknown. estimated to be between five and thirty years.
• When humans consume eggs discharged in their feces, they acquire cysticercosis, which is caused by the larval stages.
• The oncospheres that form from the eggs pass through the small intestine.
• Ingestion of eggs might come from another source or as an autoinfection in a patient who already has tapeworm.
COMMON CONNECTED CIRCUMSTANCES
• Strokes, hydrocephalus, epilepsy, and intracranial hypertension
History of Diagnosis
• Sleeplessness, anorexia, and weight loss are among the disease's symptoms.
Pain in the abdomen
Disorders of the digestive system A persistent headache
Seizures, nausea, and vomiting
Neurological symptoms that are focal
Changes in mental state; visual abnormalities or eyesight changes; and skin nodules
Living in or traveling to regions where cysticercosis is widespread; interacting with individuals who have the disease; eating undercooked ham; and asking about worm segments excreted
PHYSICAL EXAMINATION
The following are examples of physical findings:
Fever absence; typically nonfocal neurologic symptoms
The presence of intraocular larvae on ophthalmoscopy may be diagnostic, as can papilledema and reduced retinal venous pulsations.
Meningitis
Visual impairments or nystagmus; hyperreflexia
Sebaceous cyst-like subcutaneous nodules that are palpable
The pseudohypertrophy of muscles
Tests for Diagnosis and Interpretation
Lab
• Serology-full blood count; frequently missing eosinophilia
The enzyme-linked immunosorbent test is very specific and has a 74% sensitivity. As the number of cysts increases, so does sensitivity.
In patients with numerous cysts, the enzyme-linked immunoelectrotransfer blot has a sensitivity of >95% and a specificity of over 100%. Patients with a solitary cyst are poor.
Stool for parasites and ova.
Imaging techniques include soft tissue x-rays, which can reveal calcified cysts, brain CT scans, and brain MRIs, which are the preferred imaging method for detecting brainstem cysts.
Diagnostic Techniques and Other
Both lumbar puncture and biopsy or fine-needle aspiration of subcutaneous nodules are not sensitive or specific. Cerebrospinal fluid may exhibit lymphocytosis, elevated protein, and/or decreased glucose levels when there is severe inflammation.
Pathological Results
Cysts range in size from a few millimeters to 1-2 centimeters and are uniformly round or oval vesicles.
Differential diagnosis, brain tumors, brain abscess, and status epilepticus
These include encephalitis, epidural and subdural infections, meningitis, tuberculosis, hemorrhagic and ischemic strokes, subarachnoid hemorrhage, endophthalmitis, migraine, tension headaches, coccidioidomycosis, toxoplasmosis, and trichomoniasis.
MEDICATION FOR TREATMENT
First Line • Corticosteroids: Prednisone orally or dexamethasone intravenously • Anticonvulsants: Lorazepam, phenytoin, or phenobarbital • Anthelmintics (2): Praziquantel 50 mg/kg/d orally in three divided doses each day for two weeks
For two weeks, take two to three divided doses of second line albendazole (15 mg/kg/d) orally.
ADDITIONAL MEDICATION
Referral issues: • A referral to a neurologist
Seizures, changes in mental status, and other neurological symptoms
Referral to a neurosurgeon for surgical intervention to lower intracranial pressure; Referral to an ophthalmologist for changes in vision or visual problems
OTHER PROCEDURES AND SURGERY
• Interventricular shunt • Ventriculoperitoneal shunt
IN-PATIENT CONSIDERATIONS
• Burr hole to reduce intracranial pressure
First Stabilization
As needed, resuscitation in accordance with the Acute Life Support procedure
Requirements for Admission
• For IV corticosteroid therapy to lower intracranial pressure in patients with status epilepticus
• For patients needing ocular surgery
• For surgical procedures to lower intracranial pressure from obstructive hydrocephalus
Intravenous Fluids
Fluids used for maintenance that contain Ringers lactate
Nursing
Employ the proper barrier nursing strategies.
Criteria for Discharge
• Seizures are stopped; the patient is clinically stable
Continuing Care Follow-Up Suggestions
For patients with chronic CNS calcifications, long-term anticonvulsant treatment
Monitoring of Patients
MRI or follow-up CT scan to evaluate therapy response
A DIET
Before eating, pork should be cooked through.
PATIENT EDUCATION: As mentioned in "General Prevention," patients and their families should understand how to treat seizures with first aid; how to take prescribed drugs; and when to seek medical attention, particularly when to look for symptoms of elevated intracranial pressure or localized
neurologic complaints: People who have recently experienced seizures shouldn't drive, use heavy equipment, climb ladders, swim, or engage in other risky activities.
PROGNOSIS
With the right diagnosis and care, the prognosis is typically excellent.
problems include: loss of eyesight; status epilepticus; stroke; intracranial herniation; long-term anticonvulsant use; and intraventricular shunt problems.
- Published on
Infectious Disease - Cryptoporidiosis
ESSENTIALS DESCRIPTION
An internal protozoan called Cryptosporidium causes self-limited diarrhea in adults and children as well as prolonged or even fatal diarrhea in HIV-infected patients.
The study of epidemiology
The prevalence
In the United States, the condition affects about 300,000 people annually.
The frequency
• The organism is widely distributed throughout the world; seroprevalence rates can reach up to 75% in underdeveloped nations and 25% in industrialized nations; and elevated transmission is observed in temperate regions.
• In the US, there have been reports of significant waterborne epidemics linked to tainted water sources during warmer months (e.g., Milwaukee, WI).
• Dairy farms and other farms with livestock have been mostly responsible for the poisoning of water systems.
Risk factors include: AIDS patients with chronic diarrhea and a CD4 count less than 100 cells/μL; other immunosuppressive conditions; and children under five in impoverished nations. • Those who handle animals
GENERAL PREVENTION Several measures are advised for those infected with HIV, such as the following:
Steer clear of drinking from pools, rivers, or streams.
Avoiding contact with human or animal excrement; avoiding ingesting water while swimming. Particular caution must be used while handling farm animals or soil that may have been tainted by animal waste.
• It is important to check for Cryptosporidium in the stools of pets who have diarrhea.
• Most water purification techniques, including chlorination, are ineffective against the bacterium.
• When traveling to impoverished nations, stay away from drinking tap water.
• The most effective technique for removing oocysts seems to be filtration. Drinking water can be heated for one minute or filtered to 1 μ.
• Although bottled water may be safer than tap water, purity is not guaranteed and the filtering method may differ among brands.
• Drinks with carbonation are safe.
Pathophysiology
• The intracellular protozoan Cryptosporidium can infect cells that are derived from the epithelium.
• Human gastrointestinal and respiratory cells are among the impacted cells.
• One person goes through the whole life cycle.
• Ingestion of oocysts from water tainted with feces typically results in infection.
• Oocysts can endure in the environment for up to 18 months.
• Research has indicated that consuming fewer than 1000 oocysts may result in illness.
• The pathogen spreads directly from one person to another.
• Other ways that infections might spread include through the
as follows:
Pets, daycare facilities, and hospitals
Intercourse
- Pools
ETIOLOGY • C. hominis • C. meleagridis • C. parvum (most prevalent)
History of Diagnosis
• The incubation period lasts seven to ten days.
• In immunocompetent people, watery diarrhea can range in intensity from two days to a month.
• Abdominal cramps may be experienced by patients.
• There could be a low-grade temperature.
• Less likely than other diarrheal causes to induce vomiting.
• Voluminous diarrhea, up to 15 L/d, can occur in a small percentage of people with immunosuppression, such as HIV infection (mostly in those with CD4 count <50 cells />mu;L).
• Loss of weight with prolonged diarrhea.
Up to 40% of patients may experience a recurrence of the disease. Dyspnea is one of the respiratory symptoms.
Physical examination: Nonspecific results
• Malabsorption wastage
Diagnostic Examination and Interpretation Laboratory
• Giemsa-stained oocysts are seen in stool specimens.
• Round oocysts dyed red or pink against a blue-green backdrop are visible with modified acid-fast stains.
• Assays for antigen detection are more sensitive: The gold standard for feces or tissue specimen staining is now immunofluorescent antibody staining. There are also immunochromatographic or ELISA techniques available.
To find the DNA of C. parvum, use the PCR test.
Leukocytosis is uncommon.
• There are no erythrocytes or leukocytes in the feces.
• Absorption of fat is compromised.
• The majority of patients have abnormal D-Xylose testing.
• Tests for liver function usually reveal increased alkaline phosphatase.
• Low vitamin B12 levels are possible.
Imagining
• Bowel wall edema and an ileus pattern may be seen on radiographs. The results are not specific.
• Biliary involvement: The intrahepatic and extrahepatic bile ducts are dilated or irregular.
• Bilateral pulmonary infiltrates indicate respiratory involvement.
Pathological Results
An intracellular, extracytoplasmic parasite is seen protruding from the mucosal surface's brush boundary in a small intestinal sample.
DIFFERENTIAL DIAGNOSIS • Infections with Clostridium difficile • Salmonella, Shigella, and Campylobacter are examples of enteric bacterial infections
• Mycobacterial infection; • Viral gastroenteritis
• Cytomegalovirus colitis; • Giardia, Cyclospora, Isospora, and Microsporidia infections caused by enteric protozoa
MEDICATION FOR TREATMENT
First Phrase
• Anti-parasitic medications have not been shown to be effective in immunocompromised hosts.
• In patients who are not immunocompromised, nitazoxanide effectively treats diarrhea. Adults and children over the age of twelve can consume 500 mg tablets of nitazoxanide. For three days, 500 mg should be given b.i.d. with food. Nitazoxanide is available as a suspension (powder for reconstitution 100 mg/5 mL) for children aged 1–11. For children ages 1–3, take 100 mg b.i.d. (5 mL) with food for three days; for children ages 4–11, take 200 mg b.i.d. (10 mL) with food for three days. AIDS patients have benefited from the compassionate use of nitazoxanide.Adult dosages ranged from 500 to 1500 mg b.i.d., and treatment is given for at least 14 days in this compassionate use context.
• Oral nonabsorbable aminoglycoside paromomycin has been used with varying degrees of success.For adults aged 25 to
35 mg/kg for two to four weeks in divided dosages. There is no effect of paromomycin on extraintestinal cryptosporidiosis. Combine with antimotility drugs.
• Macrolides that have some activity against Cryptosporidium include azithromycin and clarithromycin.
Line Two
• Azithromycin and paromomycin combined • 600 mg of rifaximin t.i.d. p.o. for 14 days
ADDITIONAL MEDICATION
Overall Actions
• Immunocompetent patients are likely to experience a self-limited sickness that lasts anywhere from a few days to six weeks, during which supportive treatment is provided.
• Supportive care is essential for people with HIV.
Other Treatments
Opiates, loperamide, and diphenoxylate/atropine are examples of antimotility drugs.
• It has been demonstrated that octreotide reduces the production of watery stool without completely eliminating the organism.
• Immune reconstitution using extremely active antiretroviral medications works well for diarrhea in AIDS patients. Note: In vitro, protease inhibitors exhibit anti-cryptosporidial properties.
OTHER PROCEDURES AND SURGERY
In-patient considerations for cholecystectomy for acalculous cholecystitis
Requirements for Admission
Patients who are very dehydrated should be admitted to the hospital, especially kids.
Intravenous Fluids
For patients who are extremely dehydrated, parenteral hydration is used. Add more glucose, bicarbonate, potassium, and sodium.
Continuing Care Follow-Up Suggestions
• There is no need for extra monitoring in immunocompetent patients.
• In patients with HIV or other immunocompromised conditions, aggravation and remission are frequent, although organism eradication is less frequent. Those patients require close monitoring.
DIET: Control undernutrition.
• Steer clear of items that contain lactose because secondary lactose sensitivity is prevalent.
• Supplementing with glutamine may enhance fluid absorption.
PROGNOSIS
illness that goes away on its own in immunocompetent people or in AIDS patients whose CD4 count is greater than 150 cells/μL.
DIFFICULTIES
• Prolonged diarrhea is prevalent and potentially fatal in persons with HIV infection.
• Acalculous cholecystitis and sclerosing cholangitis may result from the organism's involvement of the gallbladder and bile ducts.
• Pancreatitis is possible.
• When the respiratory tract is affected, tracheitis and bronchitis may develop.
ESSENTIALS DESCRIPTION
An internal protozoan called Cryptosporidium causes self-limited diarrhea in adults and children as well as prolonged or even fatal diarrhea in HIV-infected patients.
The study of epidemiology
The prevalence
In the United States, the condition affects about 300,000 people annually.
The frequency
• The organism is widely distributed throughout the world; seroprevalence rates can reach up to 75% in underdeveloped nations and 25% in industrialized nations; and elevated transmission is observed in temperate regions.
• In the US, there have been reports of significant waterborne epidemics linked to tainted water sources during warmer months (e.g., Milwaukee, WI).
• Dairy farms and other farms with livestock have been mostly responsible for the poisoning of water systems.
Risk factors include: AIDS patients with chronic diarrhea and a CD4 count less than 100 cells/μL; other immunosuppressive conditions; and children under five in impoverished nations. • Those who handle animals
GENERAL PREVENTION Several measures are advised for those infected with HIV, such as the following:
Steer clear of drinking from pools, rivers, or streams.
Avoiding contact with human or animal excrement; avoiding ingesting water while swimming. Particular caution must be used while handling farm animals or soil that may have been tainted by animal waste.
• It is important to check for Cryptosporidium in the stools of pets who have diarrhea.
• Most water purification techniques, including chlorination, are ineffective against the bacterium.
• When traveling to impoverished nations, stay away from drinking tap water.
• The most effective technique for removing oocysts seems to be filtration. Drinking water can be heated for one minute or filtered to 1 μ.
• Although bottled water may be safer than tap water, purity is not guaranteed and the filtering method may differ among brands.
• Drinks with carbonation are safe.
Pathophysiology
• The intracellular protozoan Cryptosporidium can infect cells that are derived from the epithelium.
• Human gastrointestinal and respiratory cells are among the impacted cells.
• One person goes through the whole life cycle.
• Ingestion of oocysts from water tainted with feces typically results in infection.
• Oocysts can endure in the environment for up to 18 months.
• Research has indicated that consuming fewer than 1000 oocysts may result in illness.
• The pathogen spreads directly from one person to another.
• Other ways that infections might spread include through the
as follows:
Pets, daycare facilities, and hospitals
Intercourse
- Pools
ETIOLOGY • C. hominis • C. meleagridis • C. parvum (most prevalent)
History of Diagnosis
• The incubation period lasts seven to ten days.
• In immunocompetent people, watery diarrhea can range in intensity from two days to a month.
• Abdominal cramps may be experienced by patients.
• There could be a low-grade temperature.
• Less likely than other diarrheal causes to induce vomiting.
• Voluminous diarrhea, up to 15 L/d, can occur in a small percentage of people with immunosuppression, such as HIV infection (mostly in those with CD4 count <50 cells />mu;L).
• Loss of weight with prolonged diarrhea.
Up to 40% of patients may experience a recurrence of the disease. Dyspnea is one of the respiratory symptoms.
Physical examination: Nonspecific results
• Malabsorption wastage
Diagnostic Examination and Interpretation Laboratory
• Giemsa-stained oocysts are seen in stool specimens.
• Round oocysts dyed red or pink against a blue-green backdrop are visible with modified acid-fast stains.
• Assays for antigen detection are more sensitive: The gold standard for feces or tissue specimen staining is now immunofluorescent antibody staining. There are also immunochromatographic or ELISA techniques available.
To find the DNA of C. parvum, use the PCR test.
Leukocytosis is uncommon.
• There are no erythrocytes or leukocytes in the feces.
• Absorption of fat is compromised.
• The majority of patients have abnormal D-Xylose testing.
• Tests for liver function usually reveal increased alkaline phosphatase.
• Low vitamin B12 levels are possible.
Imagining
• Bowel wall edema and an ileus pattern may be seen on radiographs. The results are not specific.
• Biliary involvement: The intrahepatic and extrahepatic bile ducts are dilated or irregular.
• Bilateral pulmonary infiltrates indicate respiratory involvement.
Pathological Results
An intracellular, extracytoplasmic parasite is seen protruding from the mucosal surface's brush boundary in a small intestinal sample.
DIFFERENTIAL DIAGNOSIS • Infections with Clostridium difficile • Salmonella, Shigella, and Campylobacter are examples of enteric bacterial infections
• Mycobacterial infection; • Viral gastroenteritis
• Cytomegalovirus colitis; • Giardia, Cyclospora, Isospora, and Microsporidia infections caused by enteric protozoa
MEDICATION FOR TREATMENT
First Phrase
• Anti-parasitic medications have not been shown to be effective in immunocompromised hosts.
• In patients who are not immunocompromised, nitazoxanide effectively treats diarrhea. Adults and children over the age of twelve can consume 500 mg tablets of nitazoxanide. For three days, 500 mg should be given b.i.d. with food. Nitazoxanide is available as a suspension (powder for reconstitution 100 mg/5 mL) for children aged 1–11. For children ages 1–3, take 100 mg b.i.d. (5 mL) with food for three days; for children ages 4–11, take 200 mg b.i.d. (10 mL) with food for three days. AIDS patients have benefited from the compassionate use of nitazoxanide.Adult dosages ranged from 500 to 1500 mg b.i.d., and treatment is given for at least 14 days in this compassionate use context.
• Oral nonabsorbable aminoglycoside paromomycin has been used with varying degrees of success.For adults aged 25 to
35 mg/kg for two to four weeks in divided dosages. There is no effect of paromomycin on extraintestinal cryptosporidiosis. Combine with antimotility drugs.
• Macrolides that have some activity against Cryptosporidium include azithromycin and clarithromycin.
Line Two
• Azithromycin and paromomycin combined • 600 mg of rifaximin t.i.d. p.o. for 14 days
ADDITIONAL MEDICATION
Overall Actions
• Immunocompetent patients are likely to experience a self-limited sickness that lasts anywhere from a few days to six weeks, during which supportive treatment is provided.
• Supportive care is essential for people with HIV.
Other Treatments
Opiates, loperamide, and diphenoxylate/atropine are examples of antimotility drugs.
• It has been demonstrated that octreotide reduces the production of watery stool without completely eliminating the organism.
• Immune reconstitution using extremely active antiretroviral medications works well for diarrhea in AIDS patients. Note: In vitro, protease inhibitors exhibit anti-cryptosporidial properties.
OTHER PROCEDURES AND SURGERY
In-patient considerations for cholecystectomy for acalculous cholecystitis
Requirements for Admission
Patients who are very dehydrated should be admitted to the hospital, especially kids.
Intravenous Fluids
For patients who are extremely dehydrated, parenteral hydration is used. Add more glucose, bicarbonate, potassium, and sodium.
Continuing Care Follow-Up Suggestions
• There is no need for extra monitoring in immunocompetent patients.
• In patients with HIV or other immunocompromised conditions, aggravation and remission are frequent, although organism eradication is less frequent. Those patients require close monitoring.
DIET: Control undernutrition.
• Steer clear of items that contain lactose because secondary lactose sensitivity is prevalent.
• Supplementing with glutamine may enhance fluid absorption.
PROGNOSIS
illness that goes away on its own in immunocompetent people or in AIDS patients whose CD4 count is greater than 150 cells/μL.
DIFFICULTIES
• Prolonged diarrhea is prevalent and potentially fatal in persons with HIV infection.
• Acalculous cholecystitis and sclerosing cholangitis may result from the organism's involvement of the gallbladder and bile ducts.
• Pancreatitis is possible.
• When the respiratory tract is affected, tracheitis and bronchitis may develop.
- Published on
Infectious Disease - Conjunctivitis
CONJUNCTIVITIS
The basic description of conjunctivitis is that it is an inflammatory response of the conjunctiva that manifests as discharge and hyperemia. Acute or chronic, infectious or non-infectious, conjunctivitis can occur.
• Chlamydia trachomatis serotypes A–C are linked to trachoma, a persistent conjunctivitis.
• Ophthalmia neonatorum is acute mucopurulent conjunctivitis that manifests within the first month of life; • Inclusion conjunctivitis is caused by sexually transmitted C. trachomatis strains (serotypes D through K) in young adults exposed to infected genital secretions or in their newborn offspring.
The incidence of epidemiology
• In the Netherlands, there have been reports of up to 13.9 instances of infectious conjunctivitis per 1000 persons-years seen by general practitioners.
• With a reported frequency of 6.2 per 1000 live births, Chlamydia spp. are the most prevalent infectious organisms that cause ophthalmia neonatorum in the United States.
• There are now three cases of gonococcal ophthalmia neonatorum for every 1000 live births, a significant decrease from the previous 100 cases.
The frequency
• In portions of Asia, the Middle East, sub-Saharan Africa, and northern Africa, endemic trachoma is the most preventable cause of blindness.
• Trachoma still affects Native American communities and immigrants from endemic locations in the United States.
• According to WHO estimates from 2003, trachoma caused 7.6 million blind or severely visually impaired persons worldwide.
• As a result of more hygienic circumstances, trachoma incidence and severity have declined globally in recent decades.
RISK ELEMENTS
Trachoma spreads from eye to eye by hands, flies, towels, and other contact. It is strongly associated with poverty, lack of access to water, and healthcare facilities.
OVERALL PREVENTION
• Promoting general hygiene practices reduces trachoma-related morbidity.
• All sexual partners must receive treatment for adult inclusion conjunctivitis; public health measures against trachoma include the widespread application of tetracycline or erythromycin ointment to children's eyes in endemic areas for 21–60 days, or intermittently, or single-dose oral azithromycin therapy.
• Patients with viral epidemic keratoconjunctivitis (EKC) should be advised to wash their hands frequently, refrain from touching their eyes, and refrain from sharing towels or pillows with others. • Applying erythromycin or tetracycline ointment within an hour of delivery significantly reduces the risk of developing chlamydial ophthalmia neonatorum.
Pathophysiology
A disturbance of the host defensive systems, such as abnormalities of the ocular surface, abnormalities of the tear film, or systemic immunosuppression, is part of the pathogenesis of bacterial conjunctivitis.
Ethiology
Causes of Infection
• Bacteria (including Streptococcus species, Staphylococcus species, Treponema pallidum, Haemophilus species, Neisseria gonorrhoeae, Chlamydia trachomatis, and Bartonella henselae).
Adenoviruses, Coxsackie virus, echoviruses, enteroviruses, and other viruses are examples of fungi.
• Parasites (Wuchereria bancrofti, Toxocara canis, Onchocerca volvulus, and Loa loa worm) • There are four patterns of viral conjunctivitis:
Adenovirus serotypes 8, 19, and 37 are the cause of EKC.
Adenovirus serotypes 3 and 8 cause pharyngoconjunctival fever, which is more prevalent in children.
Tropical areas are more likely to get acute hemorrhagic conjunctivitis, which is brought on by enterovirus type 70 and Coxsackie virus type A24.
In connection with systemic viral illnesses including influenza, mumps, and measles
• A conjunctival reaction may also be a part of HSV and VZV ocular involvement (see "Keratitis").
• In roughly 5–10% of patients with the systemic infection, cat scratch illness caused by Bartonella henselae can result in conjunctivitis, among other symptoms. Parinaud Oculoglandular Syndrome is the term used to describe ocular involvement.
COMMON CONNECTED CIRCUMSTANCES
• The most frequent conditions linked to viral EKC are an upper respiratory tract infection or the presence of ill contacts in the home.
• Adult inclusion conjunctivitis may be associated with a history of urethritis, vaginitis, or cervicitis.
History of Diagnosis
• Patients may have eyelid edema, conjunctival injection (red eye), crying, mucous or mucopurulent discharge, or a foreign-body sensation, depending on the pathogen causing the problem. There is very little pain and only a tiny loss of visual acuity.
• Within a day or two of exposure, signs of gonococcal bacterial conjunctivitis appear in both infants and sexually active young people. When the membranes tear too soon, the incubation time for gonococcal ophthalmia neonatorum may be shortened.
• In cases of viral EKC, one eye typically becomes affected first, followed by the second eye immediately after, after an incubation period of up to one week. Light sensitivity (photophobia), fluid discharge, and a slight foreign-body sensation are all brought on by EKC.
MEDICAL EXAMINATION
• Conjunctivitis's clinical manifestations and progression are
• affected by the infection that is causing the problem.
Typically, infectious conjunctivitis manifests as discharge, eyelid edema, and hyperemia. While bacterial and allergic conjunctivitis typically exhibit a papillary reaction, which is a lymphoid hyperplasia surrounding a vascular core, viral and chlamydial conjunctivitis typically manifest as a primarily follicular conjunctival reaction. Particularly in viral conjunctivitis, the cornea may become secondary, exhibiting superficial vascularization and inflammatory infiltrations.
Depending on the infection, secretions might range from serosanguineous to purulent. While N. gonorrhoeae produces a thick, abundant, yellow-green purulent discharge, bacterial infections typically produce more mucopurulent exudates.
Among the results are conjunctival membranes and pseudomembranes.
Preauricular lymphadenopathy is frequently seen in cases of inclusion conjunctivitis, gonococcal conjunctivitis, EKC, or HSV.
A mucopurulent discharge is frequently the result of neonatal chlamydial conjunctivitis, which typically manifests acutely (5–14 days postpartum).
An early follicular reaction in the conjunctiva is linked to both inclusion conjunctivitis and trachoma. Following follicular resolution in trachoma, subconjunctival scarring develops, which results in
loss of goblet cells that produce mucin, keratitis, entropion, and trichiasis.
• Acute unilateral follicular conjunctivitis with mucopurulent discharge is the hallmark of inclusion conjunctivitis in adults. If left untreated, conjunctivitis can be persistent and last for months.
• Conjunctival hyperemia, eyelid swelling, fever, granulomatous nodules on the palpebral or bulbar conjunctiva, and regional lymphadenopathy are the symptoms of Parinaud Oculoglandular Syndrome. Neuroretinitis is another possibility.
• Several nodular or ulcerative lesions of the palpebral conjunctiva, as well as regional lymphadenopathy, are symptoms of painful purulent conjunctivitis caused by F. tularensis.
TESTS FOR DIAGNOSIS AND INTERPRETATION
Imaging First Step
Infectious conjunctivitis does not respond well to any particular modality.
Follow-up and Particular Points to Remember
Conjunctivitis in adults, genital examination, and
Both the afflicted persons and their sexual partners should undergo testing for genital chlamydial infection.
Diagnostic Techniques and Other
• Only hyperacute cases that are suggestive of N. gonorrhoeae, as well as severe, chronic, or uncommon cases, require microbiologic study.
• Gram-stained smears should be supported by cultures on blood and chocolate agar. Gram-stained smears may show gram-negative intracellular diplococci in gonococcal conjunctivitis or sporadic tiny gram-negative coccobacilli in Haemophilus conjunctivitis.
• In cases of trachoma, serum or tears may exhibit antibodies against C. trachomatis. Although isolation in cell cultures, ELISA, immunofluorescent monoclonal antibody stains, or chlamydial PCR techniques are more sensitive, 10–60% of Giemsa-stained conjunctival smears in such populations contain intracytoplasmic chlamydial inclusions in epithelial cells.
• Giemsa- or immunofluorescence-stained smears, isolation in cell cultures, or more recent non-culture methods are used to detect chlamydiae in adult inclusion conjunctivitis.
• PCR methods can be used to identify the viruses that cause viral conjunctivitis.
DIFFERENTIAL DIAGNOSIS: Infectious conjunctivitis needs to be distinguished from non-infectious conjunctivitis and from other conditions that cause red eyes. In newborns, chlamydial conjunctivitis typically has a longer incubation period (5–14 days) than gonococcal conjunctivitis (1–3 days). Examples of these entities include dry eye disease, Stevens–Johnson’s syndrome, ocular cicatricial pemphigoid (OCP), allergic/atopic/vernal conjunctivitis, exogenous irritation from pollution and medications (medicamentosa), conjunctival or eyelid tumors, and graft-versus-host disease.
FIRST LINE TREATMENT MEDICATION
• The only supportive care needed for viral conjunctivitis is the use of cold compresses and artificial tears. A topical steroid (loteprednol 0.5% q.i.d.) may be recommended if membranes or pseudomembranes are present and can be peeled off.
• To prevent corneal epithelial damage, topical antiviral treatment (trifluridine 1% five times a day) is used to treat HSV conjunctivitis. Topical steroids should not be used.
• Broad-spectrum topical antibiotics, including trimethoprim-polymyxin B (q.i.d.) or a topical fluoroquinolone (q.i.d.), are typically used empirically to treat mild cases of bacterial conjunctivitis for five to seven days. When it comes to fourth-generation fluoroquinolones (gatifloxacin or moxifloxacin), the least amount of broad-spectrum antibiotic resistance is seen.
Treatment for H. influenzae should involve oral amoxicillin/clavulanate (20–40 mg/kg/day in three divided doses).
dosages) due to sporadic extraocular involvement (e.g., meningitis, pneumonia, otitis media).
• Systemic ceftriaxone treatment is necessary for gonococcal conjunctivitis, whether or not keratitis is present. One dosage of ceftriaxone (1 g i.m.) is adequate if there is no corneal involvement; if there is corneal involvement, an intravenous dose of ceftriaxone (1 g i.v. q.d.–b.i.d.) is required in addition to a topical fourth-generation fluoroquinolone (gatifloxacin or moxifloxacin every hour, 24/7). The clinical response determines how long a treatment will last. It is also advised to treat any potential chlamydial co-infection with a single oral azithromycin dosage (1 g p.o.).
• One dosage of oral azithromycin (1 g p.o.) combined with topical erythromycin or tetracycline ophthalmic ointment used b.i.d. or t.i.d. for two to three weeks is used to treat adult inclusion conjunctivitis.
• A single dosage of azithromycin (20 mg/kg p.o.) and topical erythromycin, tetracycline, or sulfacetamide ointment (b.i.d.–q.i.d.) are used to cure trachoma for three to four weeks.
• In immune-competent hosts, cat scratch illness typically heals on its own without treatment. One option is oral azithromycin (500 mg p.o. q.i.d. for the first day and then 250 mg p.o. q.d. for the next four days). The dosage of azithromycin for children is modified to be 10 mg/kg p.o. q.i.d. on the first day and 5 mg/kg p.o. q.d. for the next four days. Topical antibiotics like eyedrops of gentamicin (q.i.d.) or
It is also possible to administer bacitracin/polymyxin B ointment (q.i.d.).
• Systemic antimicrobials should be used to treat ophthalmia neonatorum in order to prevent systemic involvement, as concurrent pharyngeal infections are frequently present:
Systemic ceftriaxone (25–50 mg/kg i.v. or i.m. to a maximum of 125 mg) combined with regular saline irrigations to eliminate the discharge is recommended for N. gonorrhoeae. To treat neonatal gonococcal ophthalmia, ceftriaxone is administered intramuscularly only once.
- C. trachomatis: topical erythromycin ointment and oral erythromycin (50 mg/kg/day p.o. in 4 split doses) for 2 weeks (q.i.d.).
Intravenous acyclovir (45–60 mg/kg/day, divided in 3 doses) should be administered to full-term infants for 2 weeks if the disease only affects the eyes, skin, and mouth, and for 3 weeks if it affects the central nervous system. It is also recommended to start topical treatment with vidarabine ointment (3% five times a day) or trifluridine eyedrops (1% nine times a day).
Line Two
• Oral erythromycin (500 mg p.o. q.i.d.) or doxycycline (100 mg p.o. b.i.d.) can also be used to treat adult inclusion conjunctivitis for seven days.
• Doxycycline is an other treatment option for trachoma.
(100 mg p.o. b.i.d.) or 500 mg p.o. q.i.d.) of erythromycin for two weeks.
• If a patient has gonococcal conjunctivitis and is allergic to penicillins, try giving them 500 mg of ciprofloxacin orally for five days. Emerging opposition, however, is a serious worry.
• Adults with cat scratch illness may get 100 mg of doxycycline p.o. b.i.d.
ADDITIONAL MEDICATION
Overall Actions
It is recommended to often irrigate the purulent discharge with saline when gonococcal conjunctivitis is present.
Referral Issues
An ID consultation should be obtained in cases of adult inclusion conjunctivitis or gonococcal infection.
OTHER PROCEDURES AND SURGERY
A conjunctival biopsy may occasionally be necessary to make a diagnosis, such as OCP.
Considering the patient
Requirements for Admission
Except for patients requiring intravenous antibiotics and ophthalmia neonatorum, conjunctivitis is treated as an outpatient condition.
PERMANENT CARE DIET
There are no dietary restrictions.
PATIENT EDUCATION Teach patients how to maintain good hygiene.
PROGNOSIS
Rarely can infectious conjunctivitis persist for longer than three weeks, with the exception of chlamydial conjunctivitis.
COMPLICATIONS
• Chronic conjunctival inflammation in trachoma causes the eyelids to deform, turning inward (trichiasis and entropion), and causes scarring. Compromise of the corneal epithelium may result in opacification and scarring.
• Subepithelial infiltrates (inflammatory superficial corneal opacities) may form in viral EKC.
nature), which would necessitate long-term topical steroid treatment.
• Infants with ophthalmia neonatorum are susceptible to systemic infections, including rhinitis, stomatitis, arthritis, meningitis, and sepsis (N. gonorrhoeae), otitis and pneumonitis (C. trachomatis), and encephalitis (HSV), as a result of exposure to pathogens during transit through the birth canal.
CONJUNCTIVITIS
The basic description of conjunctivitis is that it is an inflammatory response of the conjunctiva that manifests as discharge and hyperemia. Acute or chronic, infectious or non-infectious, conjunctivitis can occur.
• Chlamydia trachomatis serotypes A–C are linked to trachoma, a persistent conjunctivitis.
• Ophthalmia neonatorum is acute mucopurulent conjunctivitis that manifests within the first month of life; • Inclusion conjunctivitis is caused by sexually transmitted C. trachomatis strains (serotypes D through K) in young adults exposed to infected genital secretions or in their newborn offspring.
The incidence of epidemiology
• In the Netherlands, there have been reports of up to 13.9 instances of infectious conjunctivitis per 1000 persons-years seen by general practitioners.
• With a reported frequency of 6.2 per 1000 live births, Chlamydia spp. are the most prevalent infectious organisms that cause ophthalmia neonatorum in the United States.
• There are now three cases of gonococcal ophthalmia neonatorum for every 1000 live births, a significant decrease from the previous 100 cases.
The frequency
• In portions of Asia, the Middle East, sub-Saharan Africa, and northern Africa, endemic trachoma is the most preventable cause of blindness.
• Trachoma still affects Native American communities and immigrants from endemic locations in the United States.
• According to WHO estimates from 2003, trachoma caused 7.6 million blind or severely visually impaired persons worldwide.
• As a result of more hygienic circumstances, trachoma incidence and severity have declined globally in recent decades.
RISK ELEMENTS
Trachoma spreads from eye to eye by hands, flies, towels, and other contact. It is strongly associated with poverty, lack of access to water, and healthcare facilities.
OVERALL PREVENTION
• Promoting general hygiene practices reduces trachoma-related morbidity.
• All sexual partners must receive treatment for adult inclusion conjunctivitis; public health measures against trachoma include the widespread application of tetracycline or erythromycin ointment to children's eyes in endemic areas for 21–60 days, or intermittently, or single-dose oral azithromycin therapy.
• Patients with viral epidemic keratoconjunctivitis (EKC) should be advised to wash their hands frequently, refrain from touching their eyes, and refrain from sharing towels or pillows with others. • Applying erythromycin or tetracycline ointment within an hour of delivery significantly reduces the risk of developing chlamydial ophthalmia neonatorum.
Pathophysiology
A disturbance of the host defensive systems, such as abnormalities of the ocular surface, abnormalities of the tear film, or systemic immunosuppression, is part of the pathogenesis of bacterial conjunctivitis.
Ethiology
Causes of Infection
• Bacteria (including Streptococcus species, Staphylococcus species, Treponema pallidum, Haemophilus species, Neisseria gonorrhoeae, Chlamydia trachomatis, and Bartonella henselae).
Adenoviruses, Coxsackie virus, echoviruses, enteroviruses, and other viruses are examples of fungi.
• Parasites (Wuchereria bancrofti, Toxocara canis, Onchocerca volvulus, and Loa loa worm) • There are four patterns of viral conjunctivitis:
Adenovirus serotypes 8, 19, and 37 are the cause of EKC.
Adenovirus serotypes 3 and 8 cause pharyngoconjunctival fever, which is more prevalent in children.
Tropical areas are more likely to get acute hemorrhagic conjunctivitis, which is brought on by enterovirus type 70 and Coxsackie virus type A24.
In connection with systemic viral illnesses including influenza, mumps, and measles
• A conjunctival reaction may also be a part of HSV and VZV ocular involvement (see "Keratitis").
• In roughly 5–10% of patients with the systemic infection, cat scratch illness caused by Bartonella henselae can result in conjunctivitis, among other symptoms. Parinaud Oculoglandular Syndrome is the term used to describe ocular involvement.
COMMON CONNECTED CIRCUMSTANCES
• The most frequent conditions linked to viral EKC are an upper respiratory tract infection or the presence of ill contacts in the home.
• Adult inclusion conjunctivitis may be associated with a history of urethritis, vaginitis, or cervicitis.
History of Diagnosis
• Patients may have eyelid edema, conjunctival injection (red eye), crying, mucous or mucopurulent discharge, or a foreign-body sensation, depending on the pathogen causing the problem. There is very little pain and only a tiny loss of visual acuity.
• Within a day or two of exposure, signs of gonococcal bacterial conjunctivitis appear in both infants and sexually active young people. When the membranes tear too soon, the incubation time for gonococcal ophthalmia neonatorum may be shortened.
• In cases of viral EKC, one eye typically becomes affected first, followed by the second eye immediately after, after an incubation period of up to one week. Light sensitivity (photophobia), fluid discharge, and a slight foreign-body sensation are all brought on by EKC.
MEDICAL EXAMINATION
• Conjunctivitis's clinical manifestations and progression are
• affected by the infection that is causing the problem.
Typically, infectious conjunctivitis manifests as discharge, eyelid edema, and hyperemia. While bacterial and allergic conjunctivitis typically exhibit a papillary reaction, which is a lymphoid hyperplasia surrounding a vascular core, viral and chlamydial conjunctivitis typically manifest as a primarily follicular conjunctival reaction. Particularly in viral conjunctivitis, the cornea may become secondary, exhibiting superficial vascularization and inflammatory infiltrations.
Depending on the infection, secretions might range from serosanguineous to purulent. While N. gonorrhoeae produces a thick, abundant, yellow-green purulent discharge, bacterial infections typically produce more mucopurulent exudates.
Among the results are conjunctival membranes and pseudomembranes.
Preauricular lymphadenopathy is frequently seen in cases of inclusion conjunctivitis, gonococcal conjunctivitis, EKC, or HSV.
A mucopurulent discharge is frequently the result of neonatal chlamydial conjunctivitis, which typically manifests acutely (5–14 days postpartum).
An early follicular reaction in the conjunctiva is linked to both inclusion conjunctivitis and trachoma. Following follicular resolution in trachoma, subconjunctival scarring develops, which results in
loss of goblet cells that produce mucin, keratitis, entropion, and trichiasis.
• Acute unilateral follicular conjunctivitis with mucopurulent discharge is the hallmark of inclusion conjunctivitis in adults. If left untreated, conjunctivitis can be persistent and last for months.
• Conjunctival hyperemia, eyelid swelling, fever, granulomatous nodules on the palpebral or bulbar conjunctiva, and regional lymphadenopathy are the symptoms of Parinaud Oculoglandular Syndrome. Neuroretinitis is another possibility.
• Several nodular or ulcerative lesions of the palpebral conjunctiva, as well as regional lymphadenopathy, are symptoms of painful purulent conjunctivitis caused by F. tularensis.
TESTS FOR DIAGNOSIS AND INTERPRETATION
Imaging First Step
Infectious conjunctivitis does not respond well to any particular modality.
Follow-up and Particular Points to Remember
Conjunctivitis in adults, genital examination, and
Both the afflicted persons and their sexual partners should undergo testing for genital chlamydial infection.
Diagnostic Techniques and Other
• Only hyperacute cases that are suggestive of N. gonorrhoeae, as well as severe, chronic, or uncommon cases, require microbiologic study.
• Gram-stained smears should be supported by cultures on blood and chocolate agar. Gram-stained smears may show gram-negative intracellular diplococci in gonococcal conjunctivitis or sporadic tiny gram-negative coccobacilli in Haemophilus conjunctivitis.
• In cases of trachoma, serum or tears may exhibit antibodies against C. trachomatis. Although isolation in cell cultures, ELISA, immunofluorescent monoclonal antibody stains, or chlamydial PCR techniques are more sensitive, 10–60% of Giemsa-stained conjunctival smears in such populations contain intracytoplasmic chlamydial inclusions in epithelial cells.
• Giemsa- or immunofluorescence-stained smears, isolation in cell cultures, or more recent non-culture methods are used to detect chlamydiae in adult inclusion conjunctivitis.
• PCR methods can be used to identify the viruses that cause viral conjunctivitis.
DIFFERENTIAL DIAGNOSIS: Infectious conjunctivitis needs to be distinguished from non-infectious conjunctivitis and from other conditions that cause red eyes. In newborns, chlamydial conjunctivitis typically has a longer incubation period (5–14 days) than gonococcal conjunctivitis (1–3 days). Examples of these entities include dry eye disease, Stevens–Johnson’s syndrome, ocular cicatricial pemphigoid (OCP), allergic/atopic/vernal conjunctivitis, exogenous irritation from pollution and medications (medicamentosa), conjunctival or eyelid tumors, and graft-versus-host disease.
FIRST LINE TREATMENT MEDICATION
• The only supportive care needed for viral conjunctivitis is the use of cold compresses and artificial tears. A topical steroid (loteprednol 0.5% q.i.d.) may be recommended if membranes or pseudomembranes are present and can be peeled off.
• To prevent corneal epithelial damage, topical antiviral treatment (trifluridine 1% five times a day) is used to treat HSV conjunctivitis. Topical steroids should not be used.
• Broad-spectrum topical antibiotics, including trimethoprim-polymyxin B (q.i.d.) or a topical fluoroquinolone (q.i.d.), are typically used empirically to treat mild cases of bacterial conjunctivitis for five to seven days. When it comes to fourth-generation fluoroquinolones (gatifloxacin or moxifloxacin), the least amount of broad-spectrum antibiotic resistance is seen.
Treatment for H. influenzae should involve oral amoxicillin/clavulanate (20–40 mg/kg/day in three divided doses).
dosages) due to sporadic extraocular involvement (e.g., meningitis, pneumonia, otitis media).
• Systemic ceftriaxone treatment is necessary for gonococcal conjunctivitis, whether or not keratitis is present. One dosage of ceftriaxone (1 g i.m.) is adequate if there is no corneal involvement; if there is corneal involvement, an intravenous dose of ceftriaxone (1 g i.v. q.d.–b.i.d.) is required in addition to a topical fourth-generation fluoroquinolone (gatifloxacin or moxifloxacin every hour, 24/7). The clinical response determines how long a treatment will last. It is also advised to treat any potential chlamydial co-infection with a single oral azithromycin dosage (1 g p.o.).
• One dosage of oral azithromycin (1 g p.o.) combined with topical erythromycin or tetracycline ophthalmic ointment used b.i.d. or t.i.d. for two to three weeks is used to treat adult inclusion conjunctivitis.
• A single dosage of azithromycin (20 mg/kg p.o.) and topical erythromycin, tetracycline, or sulfacetamide ointment (b.i.d.–q.i.d.) are used to cure trachoma for three to four weeks.
• In immune-competent hosts, cat scratch illness typically heals on its own without treatment. One option is oral azithromycin (500 mg p.o. q.i.d. for the first day and then 250 mg p.o. q.d. for the next four days). The dosage of azithromycin for children is modified to be 10 mg/kg p.o. q.i.d. on the first day and 5 mg/kg p.o. q.d. for the next four days. Topical antibiotics like eyedrops of gentamicin (q.i.d.) or
It is also possible to administer bacitracin/polymyxin B ointment (q.i.d.).
• Systemic antimicrobials should be used to treat ophthalmia neonatorum in order to prevent systemic involvement, as concurrent pharyngeal infections are frequently present:
Systemic ceftriaxone (25–50 mg/kg i.v. or i.m. to a maximum of 125 mg) combined with regular saline irrigations to eliminate the discharge is recommended for N. gonorrhoeae. To treat neonatal gonococcal ophthalmia, ceftriaxone is administered intramuscularly only once.
- C. trachomatis: topical erythromycin ointment and oral erythromycin (50 mg/kg/day p.o. in 4 split doses) for 2 weeks (q.i.d.).
Intravenous acyclovir (45–60 mg/kg/day, divided in 3 doses) should be administered to full-term infants for 2 weeks if the disease only affects the eyes, skin, and mouth, and for 3 weeks if it affects the central nervous system. It is also recommended to start topical treatment with vidarabine ointment (3% five times a day) or trifluridine eyedrops (1% nine times a day).
Line Two
• Oral erythromycin (500 mg p.o. q.i.d.) or doxycycline (100 mg p.o. b.i.d.) can also be used to treat adult inclusion conjunctivitis for seven days.
• Doxycycline is an other treatment option for trachoma.
(100 mg p.o. b.i.d.) or 500 mg p.o. q.i.d.) of erythromycin for two weeks.
• If a patient has gonococcal conjunctivitis and is allergic to penicillins, try giving them 500 mg of ciprofloxacin orally for five days. Emerging opposition, however, is a serious worry.
• Adults with cat scratch illness may get 100 mg of doxycycline p.o. b.i.d.
ADDITIONAL MEDICATION
Overall Actions
It is recommended to often irrigate the purulent discharge with saline when gonococcal conjunctivitis is present.
Referral Issues
An ID consultation should be obtained in cases of adult inclusion conjunctivitis or gonococcal infection.
OTHER PROCEDURES AND SURGERY
A conjunctival biopsy may occasionally be necessary to make a diagnosis, such as OCP.
Considering the patient
Requirements for Admission
Except for patients requiring intravenous antibiotics and ophthalmia neonatorum, conjunctivitis is treated as an outpatient condition.
PERMANENT CARE DIET
There are no dietary restrictions.
PATIENT EDUCATION Teach patients how to maintain good hygiene.
PROGNOSIS
Rarely can infectious conjunctivitis persist for longer than three weeks, with the exception of chlamydial conjunctivitis.
COMPLICATIONS
• Chronic conjunctival inflammation in trachoma causes the eyelids to deform, turning inward (trichiasis and entropion), and causes scarring. Compromise of the corneal epithelium may result in opacification and scarring.
• Subepithelial infiltrates (inflammatory superficial corneal opacities) may form in viral EKC.
nature), which would necessitate long-term topical steroid treatment.
• Infants with ophthalmia neonatorum are susceptible to systemic infections, including rhinitis, stomatitis, arthritis, meningitis, and sepsis (N. gonorrhoeae), otitis and pneumonitis (C. trachomatis), and encephalitis (HSV), as a result of exposure to pathogens during transit through the birth canal.
- Published on
JAKOB-CREUTZFELDT DISEASE
ESSENTIAL DESCRIPTION
The neurodegenerative diseases known as transmissible spongiform encephalopathies affect both humans and animals and are chronic, progressive, and always deadly.
Sheep illness (also known as scrapie) and cow disease (also known as bovine spongiform encephalopathy, or BSE) are examples of animal-transmissible spongiform encephalopathies.
Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, Kuru (the first prion illness identified from Papua New Guinea), and deadly familial insomnia are examples of human-transmissible spongiform encephalopathies.
The most prevalent of the prion illnesses, CJD is typified by spastic dysarthria, tremor, muscle atrophy, and progressive dementia. There are several ways that CJD can manifest, including iatrogenic, familial, sporadic, and variant. The most prevalent type is sporadic.
• The only known prion disease that is transmitted from animals (BSE) to humans is variant CJD (vCJD), which was initially identified in 1996 after an outbreak that was concentrated in the United Kingdom.
• Three vCJD cases have been reported in the United States to date.
• A novel prion disease known as "proteinase-sensitive prionopathy" was identified in a group of 11 patients in 2008 and seems to run in families.
The incidence of epidemiology
• Of all spongiform encephalopathies, 85% are sporadic CJD (sCJD).
• The mean age of those with sCJD is between 50 and 60 years old, and the frequency is about 1 case per million.
• Although family cases with an autosomal dominant pattern of inheritance, like Gerstmann-Straussler-Scheinker syndrome, have been reported, the majority of cases are sporadic.
• There have been more reports of familial CJD in North Africa, the Middle East, Italy, and Slovakia.
• After corneal transplants, dural grafts, or incorrectly decontaminated neurosurgical tools and stereotactic intracerebral depth electrodes, the disease has spread.
• About 50 instances of panhypopituitarism patients receiving further cadaveric human growth hormone therapy have been documented, and in
individuals who were treated for infertility with cadaveric human gonadotropins.
RISK ELEMENTS
There is a weak association with previous exposure to farms.
Genetics Spongiform encephalopathies have been associated with certain mutations or polymorphisms in the prion gene, PRNP.
GENERAL PREVENTION: It is generally agreed that there is currently little chance of spongiform encephalopathies spreading in the United States due to the following factors:
There are sufficient laws in place to stop spongiform encephalopathies from entering the US from outside sources.
There are sufficient laws in place to stop undiscovered BSE cases from uncheckedly spreading throughout the US cattle population. There are also sufficient preventive guidelines in place to stop high-risk bovine components from contaminating goods meant for human consumption.
Pathophysiology
accumulation of aberrant host cell protein forms associated with the prion gene product, PRNP, in neural tissue.
Ethiology
Spongiform changes (small, round vacuoles) within the neuropil, neuronal loss, hypertrophy, glial cell proliferation, and the lack of significant inflammation or white matter involvement are the pathological hallmarks of CJD. The pathological changes are most severe in the cortex, but they are also frequently noticeable in the cerebellum, thalamus, and basal ganglia.
• The pathognomonic identification of prion illnesses is the presence of prion rods or plaques on electron micrographs of prepared brain material.
History of Diagnosis
• Kuru, the most well-known prion disease, is characterized by tremors (the word "kuru" means "shivering"), ataxia, and dementia.
• Up to 50 years may pass before the condition manifests itself.
• The majority of CJD patients experience myoclonus, pyramidal tract dysfunction, and rapidly advancing dementia early in the disease.
• Cognitive slowness, concentration issues, poor judgment, and memory loss are all signs of mental disability.
• Visual or other kinds of hallucinations may coexist with mood swings and emotional instability. • Cortical, subcortical, cerebellar, and spinal cord abnormalities can occur in nearly any combination. A more than 90% of patients develop myoclonus. Other motor symptoms and indicators may include choreoathetosis, clumsiness, and tremor.
• Approximately two-thirds of patients experience a parkinsonian extrapyramidal condition as the illness worsens, with
stiffness and hypokinesia. About half of patients experience extensor plantar reactions, hyperreflexia, and spasticity.
• In prion disease forms such fatal familial insomnia, autonomic (hyperthermia, hypertension, tachycardia) and endocrine (hypercortisol, growth hormone) problems may be observed.
• Patients with vCJD range in age from 19 to 41 years and have a progressive condition that leads to death between 7–23 months after beginning. • New cases of CJD have recently been reported in some European nations (mostly the United Kingdom) as a result of BSE transmission. Ataxia and early, noticeable behavioral abnormalities are among the clinical characteristics. Most people develop progressive dementia and myoclonus as later symptoms.
MEDICAL EXAMINATION
• Cognitive decline is prevalent and includes behavioral disorders, dementia, memory loss, and sleeplessness.
• More than 90% of patients have myoclonus.
• There may be cerebellar symptoms like ataxia and nystagmus.
• Up to 80% of patients may experience spasticity, hyperreflexia, and a positive Babinski sign.
Tests for Diagnosis and Interpretation Lab
• Only a brain histology investigation may provide a definitive diagnosis for all types of CJD.
• A comprehensive search for alternative processes should be initiated if cerebrospinal fluid (CSF) pleocytosis is atypical.
The sensitivity and specificity of 14-3-3, an aberrant protein, range from 60% to 90%, however it has been connected to CJD.
• Herpes, Alzheimer's disease, vascular dementia, and paraneoplastic syndromes are among the other illnesses that can potentially result in 14-3-3 increases.
• There is no doubt that mutations in the PRNP gene are linked to family occurrences of CJD, according to recent molecular genetic research. Variations in the disease's clinical phenotype within specific familial clusters may be related to a number of mutations that have been identified. Point mutations at codons 178, 200, and 210 are among them. Several CJD families also have octrepeat insertion in the PRNP gene.
• The brain-specific S 100 protein's median serum concentration is greater in CJD patients than in controls.
• The normal periodic EEG pattern typically linked to CJD is absent in vCJD.
Laboratory testing are useful in ruling out alternative causes of fast developing dementia. Prion protein plaques are widely dispersed throughout the cerebrum and cerebellum.
• Although the protein level may be slightly higher, the CSF is usually unremarkable.
• A quick diagnostic method called extraneural prion protein testing is being developed.
Imagining
• The amount of tissue loss observed on CT and MRI typically appears to be out of proportion to the severity of clinical dementia. Areas of elevated T2 signal intensity in the striatum have been seen on MRI in certain cases.
• Single-photon emission computed tomography (SPECT) examination of vCJD illness revealed decreased brain cortical perfusion.
Diagnostic Techniques and Other
• In some types, such sCJD, where sensitivity is 64% and specificity is 91%, the EEG can be a helpful diagnostic tool.
• Bilaterally synchronized sharp-wave complexes that occur at intervals of 0.5 to 2.5 will alternate with a generalized slow background to form a predicted pattern of CJD.
s and extending for 100–600 ms. • This typical EEG pattern is present in roughly 60–95% of patients, albeit it could not be seen at an early or advanced stage of the illness.
• Sharp-wave complexes may not be evident in Kuru, fatal familial insomnia, variant, or familial CJD.
Pathological Results
Small vacuoles occur inside the neuropil, giving it the distinctive spongiform look; multicentric plaques with spicules (cerebellum, mid-brain, and cerebrum) that stain for aberrant prion gene protein products, PrPSc, are PAS-positive.
DISTINCTIVE DIAGNOSIS
Alzheimer's disease, frontotemporal dementia, Lewy body dementia, alcoholism, HIV, tubercular meningitis, neurosyphilis, Whipple's disease, progressive multifocal leukoencephalopathy, lymphoma, amyloid angiopathy, metabolic abnormalities, and autoimmune disorders are among the many conditions that can also exhibit myoclonus and dementia symptoms.
MEDICATION FOR TREATMENT
• There is no specific treatment for CJD, and it is always deadly.
• In a few anecdotal case reports, amantadine has been shown to halt the advancement of the disease; however, the effects have not been repeatable.
• Other medications, including PrPSc inhibitors (chlorpromazine) and cytoprotective medicines (flupirtine), have been explored with little to no success in survival.
• Research is being done on molecular targeting and immunotherapy.
OTHER PROCEDURES AND SURGERY
For tissue diagnosis, neurosurgical services must be consulted. The high suspicion of prion disease should be communicated to all services, including pathology.
Continuing Care Follow-Up Suggestions
Sequential examinations conducted at biweekly or monthly intervals may reveal ventricular enlargement and quickly increasing brain tissue loss in certain patients.
Since there are now no treatments for PROGNOSIS disease, it is typically fatal.
ESSENTIAL DESCRIPTION
The neurodegenerative diseases known as transmissible spongiform encephalopathies affect both humans and animals and are chronic, progressive, and always deadly.
Sheep illness (also known as scrapie) and cow disease (also known as bovine spongiform encephalopathy, or BSE) are examples of animal-transmissible spongiform encephalopathies.
Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, Kuru (the first prion illness identified from Papua New Guinea), and deadly familial insomnia are examples of human-transmissible spongiform encephalopathies.
The most prevalent of the prion illnesses, CJD is typified by spastic dysarthria, tremor, muscle atrophy, and progressive dementia. There are several ways that CJD can manifest, including iatrogenic, familial, sporadic, and variant. The most prevalent type is sporadic.
• The only known prion disease that is transmitted from animals (BSE) to humans is variant CJD (vCJD), which was initially identified in 1996 after an outbreak that was concentrated in the United Kingdom.
• Three vCJD cases have been reported in the United States to date.
• A novel prion disease known as "proteinase-sensitive prionopathy" was identified in a group of 11 patients in 2008 and seems to run in families.
The incidence of epidemiology
• Of all spongiform encephalopathies, 85% are sporadic CJD (sCJD).
• The mean age of those with sCJD is between 50 and 60 years old, and the frequency is about 1 case per million.
• Although family cases with an autosomal dominant pattern of inheritance, like Gerstmann-Straussler-Scheinker syndrome, have been reported, the majority of cases are sporadic.
• There have been more reports of familial CJD in North Africa, the Middle East, Italy, and Slovakia.
• After corneal transplants, dural grafts, or incorrectly decontaminated neurosurgical tools and stereotactic intracerebral depth electrodes, the disease has spread.
• About 50 instances of panhypopituitarism patients receiving further cadaveric human growth hormone therapy have been documented, and in
individuals who were treated for infertility with cadaveric human gonadotropins.
RISK ELEMENTS
There is a weak association with previous exposure to farms.
Genetics Spongiform encephalopathies have been associated with certain mutations or polymorphisms in the prion gene, PRNP.
GENERAL PREVENTION: It is generally agreed that there is currently little chance of spongiform encephalopathies spreading in the United States due to the following factors:
There are sufficient laws in place to stop spongiform encephalopathies from entering the US from outside sources.
There are sufficient laws in place to stop undiscovered BSE cases from uncheckedly spreading throughout the US cattle population. There are also sufficient preventive guidelines in place to stop high-risk bovine components from contaminating goods meant for human consumption.
Pathophysiology
accumulation of aberrant host cell protein forms associated with the prion gene product, PRNP, in neural tissue.
Ethiology
Spongiform changes (small, round vacuoles) within the neuropil, neuronal loss, hypertrophy, glial cell proliferation, and the lack of significant inflammation or white matter involvement are the pathological hallmarks of CJD. The pathological changes are most severe in the cortex, but they are also frequently noticeable in the cerebellum, thalamus, and basal ganglia.
• The pathognomonic identification of prion illnesses is the presence of prion rods or plaques on electron micrographs of prepared brain material.
History of Diagnosis
• Kuru, the most well-known prion disease, is characterized by tremors (the word "kuru" means "shivering"), ataxia, and dementia.
• Up to 50 years may pass before the condition manifests itself.
• The majority of CJD patients experience myoclonus, pyramidal tract dysfunction, and rapidly advancing dementia early in the disease.
• Cognitive slowness, concentration issues, poor judgment, and memory loss are all signs of mental disability.
• Visual or other kinds of hallucinations may coexist with mood swings and emotional instability. • Cortical, subcortical, cerebellar, and spinal cord abnormalities can occur in nearly any combination. A more than 90% of patients develop myoclonus. Other motor symptoms and indicators may include choreoathetosis, clumsiness, and tremor.
• Approximately two-thirds of patients experience a parkinsonian extrapyramidal condition as the illness worsens, with
stiffness and hypokinesia. About half of patients experience extensor plantar reactions, hyperreflexia, and spasticity.
• In prion disease forms such fatal familial insomnia, autonomic (hyperthermia, hypertension, tachycardia) and endocrine (hypercortisol, growth hormone) problems may be observed.
• Patients with vCJD range in age from 19 to 41 years and have a progressive condition that leads to death between 7–23 months after beginning. • New cases of CJD have recently been reported in some European nations (mostly the United Kingdom) as a result of BSE transmission. Ataxia and early, noticeable behavioral abnormalities are among the clinical characteristics. Most people develop progressive dementia and myoclonus as later symptoms.
MEDICAL EXAMINATION
• Cognitive decline is prevalent and includes behavioral disorders, dementia, memory loss, and sleeplessness.
• More than 90% of patients have myoclonus.
• There may be cerebellar symptoms like ataxia and nystagmus.
• Up to 80% of patients may experience spasticity, hyperreflexia, and a positive Babinski sign.
Tests for Diagnosis and Interpretation Lab
• Only a brain histology investigation may provide a definitive diagnosis for all types of CJD.
• A comprehensive search for alternative processes should be initiated if cerebrospinal fluid (CSF) pleocytosis is atypical.
The sensitivity and specificity of 14-3-3, an aberrant protein, range from 60% to 90%, however it has been connected to CJD.
• Herpes, Alzheimer's disease, vascular dementia, and paraneoplastic syndromes are among the other illnesses that can potentially result in 14-3-3 increases.
• There is no doubt that mutations in the PRNP gene are linked to family occurrences of CJD, according to recent molecular genetic research. Variations in the disease's clinical phenotype within specific familial clusters may be related to a number of mutations that have been identified. Point mutations at codons 178, 200, and 210 are among them. Several CJD families also have octrepeat insertion in the PRNP gene.
• The brain-specific S 100 protein's median serum concentration is greater in CJD patients than in controls.
• The normal periodic EEG pattern typically linked to CJD is absent in vCJD.
Laboratory testing are useful in ruling out alternative causes of fast developing dementia. Prion protein plaques are widely dispersed throughout the cerebrum and cerebellum.
• Although the protein level may be slightly higher, the CSF is usually unremarkable.
• A quick diagnostic method called extraneural prion protein testing is being developed.
Imagining
• The amount of tissue loss observed on CT and MRI typically appears to be out of proportion to the severity of clinical dementia. Areas of elevated T2 signal intensity in the striatum have been seen on MRI in certain cases.
• Single-photon emission computed tomography (SPECT) examination of vCJD illness revealed decreased brain cortical perfusion.
Diagnostic Techniques and Other
• In some types, such sCJD, where sensitivity is 64% and specificity is 91%, the EEG can be a helpful diagnostic tool.
• Bilaterally synchronized sharp-wave complexes that occur at intervals of 0.5 to 2.5 will alternate with a generalized slow background to form a predicted pattern of CJD.
s and extending for 100–600 ms. • This typical EEG pattern is present in roughly 60–95% of patients, albeit it could not be seen at an early or advanced stage of the illness.
• Sharp-wave complexes may not be evident in Kuru, fatal familial insomnia, variant, or familial CJD.
Pathological Results
Small vacuoles occur inside the neuropil, giving it the distinctive spongiform look; multicentric plaques with spicules (cerebellum, mid-brain, and cerebrum) that stain for aberrant prion gene protein products, PrPSc, are PAS-positive.
DISTINCTIVE DIAGNOSIS
Alzheimer's disease, frontotemporal dementia, Lewy body dementia, alcoholism, HIV, tubercular meningitis, neurosyphilis, Whipple's disease, progressive multifocal leukoencephalopathy, lymphoma, amyloid angiopathy, metabolic abnormalities, and autoimmune disorders are among the many conditions that can also exhibit myoclonus and dementia symptoms.
MEDICATION FOR TREATMENT
• There is no specific treatment for CJD, and it is always deadly.
• In a few anecdotal case reports, amantadine has been shown to halt the advancement of the disease; however, the effects have not been repeatable.
• Other medications, including PrPSc inhibitors (chlorpromazine) and cytoprotective medicines (flupirtine), have been explored with little to no success in survival.
• Research is being done on molecular targeting and immunotherapy.
OTHER PROCEDURES AND SURGERY
For tissue diagnosis, neurosurgical services must be consulted. The high suspicion of prion disease should be communicated to all services, including pathology.
Continuing Care Follow-Up Suggestions
Sequential examinations conducted at biweekly or monthly intervals may reveal ventricular enlargement and quickly increasing brain tissue loss in certain patients.
Since there are now no treatments for PROGNOSIS disease, it is typically fatal.
- Published on
Infectious Disease - Cryptococcal Infections
Basics: Cryptococcus is a type of yeast that has a special polysaccharide capsule surrounding its membrane.
• Although Cryptococcus has more than 50 species, the two most significant for medicine are Cryptococcus neoformans, which mainly infects immunocompromised patients, and Cryptococcus gattii, which also infects immunocompetent hosts.
• Cryptococcus infections can spread to any part of the body, including the bones, skin, prostate, and eyes, although they usually affect the lung or central nervous system in patients with compromised cell-mediated immunity (such as those with AIDS or organ transplantation).
• Inhalation is the main way that infections are spread. It has a preference for the central nervous system and can spread throughout the body.
The study of epidemiology
• Pigeon feces are linked to C. neoformans, which is more prevalent in the US, but direct there is no evidence of transfer from pigeons to people.
• C. gattii is typically found in the vegetation surrounding eucalyptus trees in tropical and subtropical areas. More recently, it has been observed in North America, particularly in British Columbia and the Pacific Northwest.
• There have been no reports of respiratory transmission between people or between humans and other animals. Rare situations, such transplanting an infected organ into a recipient who is not infected, can result in human-to-human transmission.
• Since the widespread use of antiretroviral medication, cryptococcal infection has significantly decreased in patients with HIV.
• For instance, following extensive antiretroviral therapy, a research assessing the incidence of cryptococcal infection in AIDS patients per 1000 people found that it had decreased from 66 to 7 in Atlanta and from 24 to 2 in Houston (1,2).
• 20–60% of cryptococcal infections in individuals without HIV in the United States are caused by Cryptococcus, the third most prevalent invasive fungal infection in solid-organ transplant recipients (3).
AIDS is a risk factor.
• Haematologic cancers.
• Transplanting solid organs
• Immunosuppressive drugs, such as tacrolimus, cyclosporine, and glucocorticoids.
• Other: Chronic obstructive pulmonary disease, diabetes mellitus, lupus, rheumatoid arthritis, splenectomy, and sarcoidosis
OVERALL PREVENTION
• HIV patients: Use antiretroviral medication to rebuild the immune system.
• Individuals with AIDS: Antiretroviral therapy can help rebuild the immune system, and fluconazole and itraconazole can help prevent cryptococcal infection in people with a CD4 cell count below 50 cells/μL. However, few HIV providers put patients on primary prophylactic regimens because of drug interactions and the lack of survival benefits with this approach.
• Secondary prophylaxis: Fluconazole (200 mg/d PO) should be administered to AIDS patients who have finished therapy for cryptococcal meningitis for the rest of their lives, or until their CD4 count is higher than 200 cells/μL for more than six months.
Pathophysiology
Spores of yeast are inhaled into the alveoli. Individuals with T cell
Deficits increase the risk of infection spreading. Primary infections are represented by pneumonia, while disseminated diseases are represented by meningitis, skin lesions, or involvement of other organs (such as the prostate, bone, etc.).
Ethiology
Among the species that are clinically significant are C. gattii and C. neoformans.
History of Diagnosis
The symptoms of a lung infection can include fever, hemoptysis, coughing, pleuritic chest discomfort, dyspnea, and acute respiratory distress syndrome.
• CNS infection: Usually manifests as headache, fever, and irritability with a subacute onset that lasts 1-3 weeks. It can then develop to disorientation, nausea, somnolence, and seizures. Just 25% of patients exhibit the typical meningitis symptoms, which include fever, photophonophobia, nausea, vomiting, and stiff neck.
MEDICAL EXAMINATION
• CNS: Usually, nuchal stiffness is not the main symptom. Rarely, cryptococcomas can cause focal neurologic impairments.
• Nearly one-third of patients have papilledema.
• Skin: Papules, ulcers, or painless sores. Skin findings could feature a molluscum contagiosum-like central umbilication.
Diagnostic Examination and Interpretation Laboratory
For cryptococcal antigen, send blood. Cryptococcus can also develop in blood cultures, and if cultures are taken in fungal isolator tubes, the test's yield will be higher.
•
• Lung infection: culture of sputum or lung nodule biopsy. If there is no growth, lung biopsy histopathology may be useful.
India ink staining, culture, and the identification of cryptococcal antigen in CSF are all crucial diagnostic tools for CNS infections.
• Usually, the CSF opening pressure is higher than 200 mm H2O.
• A CSF investigation reveals lymphocytic pleocytosis, low glucose, and high protein.
• When individuals have similar symptoms, a serum test for cryptococcal antigen can frequently be used to diagnose meningitis or pneumonia.
• Skin biopsy for cultures and fungus staining.
Imagining
• Lung infection: If there are pulmonary symptoms, a CT scan and CXR are useful. Infiltrates of interstitial
are frequently seen in patients with impaired immune systems. Both immunocompetent and immunocompromised hosts may exhibit one or more pulmonary nodules. Cavitation is uncommon. It is also possible to see a cryptococcoma, hilar or mediastinal lymphadenopathy, and pleural effusions (5).
• CNS infection: When focal neurologic impairments are apparent, a CT or MRI scan can be useful. Check for hydrocephalus, cryptococcomas, or nodules.
Pneumonia, Pneumocystis Carinii Pneumonia, TB, Sarcoidosis, Histoplasmosis, Coccidiomycosis, Meningoencephalitis, and CNS metastases are examples of differential diagnoses.
MEDICATION FOR TREATMENT
First Phrase
• Lung infection: Fluconazole 400 mg/d for 6–12 months is recommended for mild-to-moderate infections.
• CNS infection: Amphotericin B (using a lipid formulation in patients at risk of nephrotoxicity) and flucytosine 100 mg/kg/d, divided into 4 doses daily, are administered for 14 (or more) days during the first "induction phase." A "consolidation phase" of 400 mg/d of fluconazole is administered for 8 weeks, followed by "maintenance" therapy with 200 mg/d of fluconazole if patients exhibit a clinical response.
Line Two
• Itraconazole, voriconazole, and posaconazole are substitute active medicines for pneumonia.
• For those who are unable to tolerate amphotericin B plus flucytosine during the consolidation phase, fluconazole plus flucytosine is an option for CNS disease;
But this is not a good enough treatment.
ADDITIONAL MEDICATION
Overall Actions
Patients with cryptococcal infections are frequently treated by infectious disease specialists.
OTHER PROCEDURES AND SURGERY
During lumbar puncture, patients may experience opening pressures that are consistently elevated. To alleviate elevated intracranial pressures, patients with persistent neurologic symptoms (such as papilledema or lower limb clonus) should have repeated lumbar punctures. In severe cases that do not respond to serial lumbar punctures, neurosurgeon services should be consulted in order to consider ventriculoperitoneal shunting.
Continuing Care Follow-Up Suggestions
• Tracking creatinine and BUN while taking flucytosine and amphotericin.
• Keeping an eye on liver function tests when using fluconazole.
COMPLICATIONS
• Visual impairment • Dementia • Death • Hydrocephalus
Basics: Cryptococcus is a type of yeast that has a special polysaccharide capsule surrounding its membrane.
• Although Cryptococcus has more than 50 species, the two most significant for medicine are Cryptococcus neoformans, which mainly infects immunocompromised patients, and Cryptococcus gattii, which also infects immunocompetent hosts.
• Cryptococcus infections can spread to any part of the body, including the bones, skin, prostate, and eyes, although they usually affect the lung or central nervous system in patients with compromised cell-mediated immunity (such as those with AIDS or organ transplantation).
• Inhalation is the main way that infections are spread. It has a preference for the central nervous system and can spread throughout the body.
The study of epidemiology
• Pigeon feces are linked to C. neoformans, which is more prevalent in the US, but direct there is no evidence of transfer from pigeons to people.
• C. gattii is typically found in the vegetation surrounding eucalyptus trees in tropical and subtropical areas. More recently, it has been observed in North America, particularly in British Columbia and the Pacific Northwest.
• There have been no reports of respiratory transmission between people or between humans and other animals. Rare situations, such transplanting an infected organ into a recipient who is not infected, can result in human-to-human transmission.
• Since the widespread use of antiretroviral medication, cryptococcal infection has significantly decreased in patients with HIV.
• For instance, following extensive antiretroviral therapy, a research assessing the incidence of cryptococcal infection in AIDS patients per 1000 people found that it had decreased from 66 to 7 in Atlanta and from 24 to 2 in Houston (1,2).
• 20–60% of cryptococcal infections in individuals without HIV in the United States are caused by Cryptococcus, the third most prevalent invasive fungal infection in solid-organ transplant recipients (3).
AIDS is a risk factor.
• Haematologic cancers.
• Transplanting solid organs
• Immunosuppressive drugs, such as tacrolimus, cyclosporine, and glucocorticoids.
• Other: Chronic obstructive pulmonary disease, diabetes mellitus, lupus, rheumatoid arthritis, splenectomy, and sarcoidosis
OVERALL PREVENTION
• HIV patients: Use antiretroviral medication to rebuild the immune system.
• Individuals with AIDS: Antiretroviral therapy can help rebuild the immune system, and fluconazole and itraconazole can help prevent cryptococcal infection in people with a CD4 cell count below 50 cells/μL. However, few HIV providers put patients on primary prophylactic regimens because of drug interactions and the lack of survival benefits with this approach.
• Secondary prophylaxis: Fluconazole (200 mg/d PO) should be administered to AIDS patients who have finished therapy for cryptococcal meningitis for the rest of their lives, or until their CD4 count is higher than 200 cells/μL for more than six months.
Pathophysiology
Spores of yeast are inhaled into the alveoli. Individuals with T cell
Deficits increase the risk of infection spreading. Primary infections are represented by pneumonia, while disseminated diseases are represented by meningitis, skin lesions, or involvement of other organs (such as the prostate, bone, etc.).
Ethiology
Among the species that are clinically significant are C. gattii and C. neoformans.
History of Diagnosis
The symptoms of a lung infection can include fever, hemoptysis, coughing, pleuritic chest discomfort, dyspnea, and acute respiratory distress syndrome.
• CNS infection: Usually manifests as headache, fever, and irritability with a subacute onset that lasts 1-3 weeks. It can then develop to disorientation, nausea, somnolence, and seizures. Just 25% of patients exhibit the typical meningitis symptoms, which include fever, photophonophobia, nausea, vomiting, and stiff neck.
MEDICAL EXAMINATION
• CNS: Usually, nuchal stiffness is not the main symptom. Rarely, cryptococcomas can cause focal neurologic impairments.
• Nearly one-third of patients have papilledema.
• Skin: Papules, ulcers, or painless sores. Skin findings could feature a molluscum contagiosum-like central umbilication.
Diagnostic Examination and Interpretation Laboratory
For cryptococcal antigen, send blood. Cryptococcus can also develop in blood cultures, and if cultures are taken in fungal isolator tubes, the test's yield will be higher.
•
• Lung infection: culture of sputum or lung nodule biopsy. If there is no growth, lung biopsy histopathology may be useful.
India ink staining, culture, and the identification of cryptococcal antigen in CSF are all crucial diagnostic tools for CNS infections.
• Usually, the CSF opening pressure is higher than 200 mm H2O.
• A CSF investigation reveals lymphocytic pleocytosis, low glucose, and high protein.
• When individuals have similar symptoms, a serum test for cryptococcal antigen can frequently be used to diagnose meningitis or pneumonia.
• Skin biopsy for cultures and fungus staining.
Imagining
• Lung infection: If there are pulmonary symptoms, a CT scan and CXR are useful. Infiltrates of interstitial
are frequently seen in patients with impaired immune systems. Both immunocompetent and immunocompromised hosts may exhibit one or more pulmonary nodules. Cavitation is uncommon. It is also possible to see a cryptococcoma, hilar or mediastinal lymphadenopathy, and pleural effusions (5).
• CNS infection: When focal neurologic impairments are apparent, a CT or MRI scan can be useful. Check for hydrocephalus, cryptococcomas, or nodules.
Pneumonia, Pneumocystis Carinii Pneumonia, TB, Sarcoidosis, Histoplasmosis, Coccidiomycosis, Meningoencephalitis, and CNS metastases are examples of differential diagnoses.
MEDICATION FOR TREATMENT
First Phrase
• Lung infection: Fluconazole 400 mg/d for 6–12 months is recommended for mild-to-moderate infections.
• CNS infection: Amphotericin B (using a lipid formulation in patients at risk of nephrotoxicity) and flucytosine 100 mg/kg/d, divided into 4 doses daily, are administered for 14 (or more) days during the first "induction phase." A "consolidation phase" of 400 mg/d of fluconazole is administered for 8 weeks, followed by "maintenance" therapy with 200 mg/d of fluconazole if patients exhibit a clinical response.
Line Two
• Itraconazole, voriconazole, and posaconazole are substitute active medicines for pneumonia.
• For those who are unable to tolerate amphotericin B plus flucytosine during the consolidation phase, fluconazole plus flucytosine is an option for CNS disease;
But this is not a good enough treatment.
ADDITIONAL MEDICATION
Overall Actions
Patients with cryptococcal infections are frequently treated by infectious disease specialists.
OTHER PROCEDURES AND SURGERY
During lumbar puncture, patients may experience opening pressures that are consistently elevated. To alleviate elevated intracranial pressures, patients with persistent neurologic symptoms (such as papilledema or lower limb clonus) should have repeated lumbar punctures. In severe cases that do not respond to serial lumbar punctures, neurosurgeon services should be consulted in order to consider ventriculoperitoneal shunting.
Continuing Care Follow-Up Suggestions
• Tracking creatinine and BUN while taking flucytosine and amphotericin.
• Keeping an eye on liver function tests when using fluconazole.
COMPLICATIONS
• Visual impairment • Dementia • Death • Hydrocephalus
- Published on
Infectious Disease – Common Cold
COMMON COLD BASICS DESCRIPTION
Acute viral infection of the upper respiratory tract
The study of epidemiology
The prevalence
• Two to four colds are reported annually by the average adult.
• Children often report six to ten colds annually.
The frequency
RISK FACTORS
An estimated 1 billion colds occur in the US each year.
• Winter, which causes individuals to congregate inside; • Hand contact with an infected person; • Remaining in a confined space with an infected person
• People with immunocompromised conditions; • Children with undeveloped immune systems
• Psychological stress and smoking enhance susceptibility
GENERAL PREVENTION:
• Wash your hands often; • Avoid touching your nose or eyes.
PATHOPHYSIOLOGY:
A contagious viral infectious disease of the upper respiratory system, it is spread by infected people's aerosol, nasal secretions, or saliva.
• Self-restricting
Etiology
• Coronavirus (10–15%) • Rhinovirus (30–50%)
• Influenza (5–15%)
• Less often are respiratory syncytial virus, adenovirus, enterovirus, metapneumovirus, and parainfluenza.
Acute bronchitis, pharyngitis, pharyngolaryngitis, and rhinorrhea
History of Diagnosis
• 1–3 Rhinorrhea
Sneezing, nasal blockage, laryngitis or throat irritation, coughing, chilliness, and occasionally conjunctivitis, headaches, muscle aches, shivering, and anorexia
PHYSICAL EXAMINATION • Symptoms of upper respiratory tract illness • Fever is unusual
Initial laboratory testing for diagnosis and interpretation
Unless a differential diagnosis is required or problems are expected, no laboratory testing is necessary.
Follow-up and Particular Points to Remember
usually not necessary unless problems are suspected or a differential diagnosis is sought.
Imaging First Step
Not necessary unless problems are suspected or a differential diagnosis is sought.
Follow-up and Particular Points to Remember
Not necessary unless problems are suspected or a differential diagnosis is sought.
Diagnostic/Other Procedures: Usually not necessary
Isolating viruses and directly detecting their antigens
Serology-tests for virus neutralization Sputum and/or throat culture
Testing for influenza viruses
- Nasal discharge culture
DIAGNOSIS DIFFERENTIAL:Infectious
Pneumonia, whooping cough, sinusitis, and influenza are all considered noninfectious.
The condition known as allergic rhinitis
MEDICATION FOR TREATMENT
No antiviral medications with proven benefits
ADDITIONAL MEDICATION
Overall Actions
• Acetaminophen, ibuprofen, and aspirin to treat fever and aches and pains (4)
• Decongestants: Nasal: Rebound effect in individuals who use them for longer than three days; oral: Benefits uncertain
Ipratropium bromide nasal spray: Suggested for both children and adults with nasal congestion; Dextromethorphan: A cough remedy for adults; Antihistamines: First-generation antihistamines to alleviate symptoms in adults
Considerations for Children
• Due to the possibility of Reye's syndrome, children and teenagers should not use aspirin.
• Children should not use codeine, dextromethorphan, or antihistamines.
Referral Issues
Extreme symptoms
Other Treatments
Zinc, vitamin C, and echinacea (5) are not advised for active treatment.
Continuing Care Follow-Up Suggestions
If a cough lasts more than three weeks, it may be a sign of pertussis or pneumonia.
Monitoring of Patients
DIET is typically not necessary.
Drinking lots of water is advised.
PATIENT EDUCATION: Stress that the common cold does not require antibiotics.
Reduce contact with cold-stricken individuals; wash your hands frequently, avoid sharing towels, and drink lots of water. Advise against using nasal drops or sprays excessively as they may create rebound congestion.
• To prevent droplets from spreading, cover your mouth and nose with your arm instead of your hands when you cough or sneeze.
PROGNOSIS
In most cases, the illness is mild and self-limiting.
DIFFICULTIES
Pneumonia, otitis media, sinusitis, pharyngitis, acute bronchitis, and exacerbation of asthma, obstructive sleep apnea, and chronic bronchitis
COMMON COLD BASICS DESCRIPTION
Acute viral infection of the upper respiratory tract
The study of epidemiology
The prevalence
• Two to four colds are reported annually by the average adult.
• Children often report six to ten colds annually.
The frequency
RISK FACTORS
An estimated 1 billion colds occur in the US each year.
• Winter, which causes individuals to congregate inside; • Hand contact with an infected person; • Remaining in a confined space with an infected person
• People with immunocompromised conditions; • Children with undeveloped immune systems
• Psychological stress and smoking enhance susceptibility
GENERAL PREVENTION:
• Wash your hands often; • Avoid touching your nose or eyes.
PATHOPHYSIOLOGY:
A contagious viral infectious disease of the upper respiratory system, it is spread by infected people's aerosol, nasal secretions, or saliva.
• Self-restricting
Etiology
• Coronavirus (10–15%) • Rhinovirus (30–50%)
• Influenza (5–15%)
• Less often are respiratory syncytial virus, adenovirus, enterovirus, metapneumovirus, and parainfluenza.
Acute bronchitis, pharyngitis, pharyngolaryngitis, and rhinorrhea
History of Diagnosis
• 1–3 Rhinorrhea
Sneezing, nasal blockage, laryngitis or throat irritation, coughing, chilliness, and occasionally conjunctivitis, headaches, muscle aches, shivering, and anorexia
PHYSICAL EXAMINATION • Symptoms of upper respiratory tract illness • Fever is unusual
Initial laboratory testing for diagnosis and interpretation
Unless a differential diagnosis is required or problems are expected, no laboratory testing is necessary.
Follow-up and Particular Points to Remember
usually not necessary unless problems are suspected or a differential diagnosis is sought.
Imaging First Step
Not necessary unless problems are suspected or a differential diagnosis is sought.
Follow-up and Particular Points to Remember
Not necessary unless problems are suspected or a differential diagnosis is sought.
Diagnostic/Other Procedures: Usually not necessary
Isolating viruses and directly detecting their antigens
Serology-tests for virus neutralization Sputum and/or throat culture
Testing for influenza viruses
- Nasal discharge culture
DIAGNOSIS DIFFERENTIAL:Infectious
Pneumonia, whooping cough, sinusitis, and influenza are all considered noninfectious.
The condition known as allergic rhinitis
MEDICATION FOR TREATMENT
No antiviral medications with proven benefits
ADDITIONAL MEDICATION
Overall Actions
• Acetaminophen, ibuprofen, and aspirin to treat fever and aches and pains (4)
• Decongestants: Nasal: Rebound effect in individuals who use them for longer than three days; oral: Benefits uncertain
Ipratropium bromide nasal spray: Suggested for both children and adults with nasal congestion; Dextromethorphan: A cough remedy for adults; Antihistamines: First-generation antihistamines to alleviate symptoms in adults
Considerations for Children
• Due to the possibility of Reye's syndrome, children and teenagers should not use aspirin.
• Children should not use codeine, dextromethorphan, or antihistamines.
Referral Issues
Extreme symptoms
Other Treatments
Zinc, vitamin C, and echinacea (5) are not advised for active treatment.
Continuing Care Follow-Up Suggestions
If a cough lasts more than three weeks, it may be a sign of pertussis or pneumonia.
Monitoring of Patients
DIET is typically not necessary.
Drinking lots of water is advised.
PATIENT EDUCATION: Stress that the common cold does not require antibiotics.
Reduce contact with cold-stricken individuals; wash your hands frequently, avoid sharing towels, and drink lots of water. Advise against using nasal drops or sprays excessively as they may create rebound congestion.
• To prevent droplets from spreading, cover your mouth and nose with your arm instead of your hands when you cough or sneeze.
PROGNOSIS
In most cases, the illness is mild and self-limiting.
DIFFICULTIES
Pneumonia, otitis media, sinusitis, pharyngitis, acute bronchitis, and exacerbation of asthma, obstructive sleep apnea, and chronic bronchitis
